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Summary 
 
Buruli ulcer (BU) is a debilitating skin disease caused by Mycobacterium ulcerans. In the last 
decades, the disease has been reported from 34 countries with endemic foci typically occurring 
in rural areas where access to medical health facilities is a challenge. Since the exact mode of 
transmission of the pathogen is still not fully elucidated, early case detection and treatment of 
patients are key factors to control the disease. 
The first ever national active BU case search conducted in Ghana in 1999 identified the Offin 
river valley as one of the most BU endemic regions in Ghana. Based on recent anecdotal 
accounts indicating unstable transmission of M. ulcerans along the Offin river, we conducted as 
part of this PhD study, an exhaustive case search and household survey of 13 selected 
communities along the river. We observed an overall decline in the prevalence of BU. 
Subsequently, we installed an active surveillance system enabling the continued monitoring of 
the emergence of cases at the household level. By this system we were able to demonstrate that 
integration of control of several neglected tropical diseases such as leprosy and yaws was 
feasible and should be pursued to maximize the limited resources available for the control of 
these neglected tropical diseases. 
Until now, reservoirs and/or vectors of M. ulcerans are yet to be identified particularly for 
endemic settings in Africa. In the course of this PhD thesis, we conducted sero-epidemiological 
studies, assessing the exposure of populations sampled from Ghana and Cameroon to the 
pathogen by measuring humoral responses against the M. ulcerans-specific 18kDa small heat 
shock protein. We observed that exposure to M. ulcerans begins at approximately four years of 
age, coinciding with the age when children move out of their households and have more intense 
contact with the environment. Furthermore, by comparing the age when first humoral immune 
responses to M. ulcerans and to other pathogens with different modes of transmission occur, we 
observed an earlier onset of serological response to antigens of the mosquito transmitted malaria 
parasite P. falciparum and of soil transmitted Strongyloides helminths. In contrast, exposure to 
antigens of water transmitted Schistosoma worms shared a similar pattern of late onset of 
immune response with what we observed for M. ulcerans. Our data indicate that transmission of 
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M. ulcerans occurs by contact with environmental sources of the pathogen outside of the small 
movement range of very young children.  
In recent years, the prevailing assumption was that the reservoir of M. ulcerans is somewhat 
fixed in space due to the highly focal occurrence of BU outbreaks. In this regard, a strong link 
between genotype and geographical origin of clinical M. ulcerans isolates has been reported. We 
compared whole genome sequences of a limited collection of clinical M. ulcerans strains, 
isolated from individuals living in the Offin river valley and identified two co-existing clonal 
complexes not separated in time and geographical location along the Offin river. To this 
observation we infer the presence of a reservoir of infection that is more mobile than previously 
assumed.  
Since prevention is complicated by elusive transmission pathways combined with the lack of a 
vaccine, the control of BU relies on adequate treatment of patients. To date, rifampicin is the 
only effective drug against BU. However, rifampicin hepatitis is a commonly reported side effect 
of rifampicin which is known to be aggravated in tuberculosis patients with pre–existing 
infection with the hepatitis B virus (HBV). We assessed the burden of HBV in the BU endemic 
Offin river basin by analyzing serum samples of the general population for the presence of the 
hepatitis B surface antigen (HBsAg). The overall serum HBsAg prevalence was high with 8% of 
the population being chronic carriers. If stratified by age, we observed a low serum HBsAg rate 
of 1.8% among children below 12 years of age compared to 11.1% for participants older than 12 
years. By phylogenetic analysis based on the pre-S/S region of HBV, we could classify all 
isolates obtained from the Offin river basin as genotype E and serotype ayw4. In addition we 
identified two main HBV/E clusters. While one cluster was composed of only strains from the 
Offin river basin, the second cluster was in addition to Offin isolates also made up of strains 
from other parts of Ghana and West African countries like Niger, Nigeria and Benin. We 
conclude that transmission of HBV along the Offin river is mainly horizontal and recommend 
strict adhesion to vaccination protocols and periodic screening of populations within the river 
basin. 
Altogether, the multi-disciplinary approach of this PhD thesis to investigating various aspects of 
M. ulcerans transmission and epidemiology has resulted in key finding which add to the existing 
knowledge of the pathogen in Ghana and globally. 
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Zusammenfassung 
 
Buruli-Ulkus (BU) ist eine durch Mycobacterium ulcerans hervorgerufene, verheerende 
Hauterkrankung. Das Auftreten dieser Krankheit wurde in den letzten Jahrzenten aus insgesamt 
34 Ländern gemeldet, wobei die Infektionsbrennpunkte typischerweise in ländlichen Regionen 
liegen, in denen der Zugang zu medizinischen Gesundheitseinrichtungen eine Herausforderung 
darstellt. Da die Übertragungswege des Erregers bis heute nicht vollständig geklärt sind, ist die 
Erkennung und Behandlung von Patienten in möglichst frühen Krankheitsstadien die primäre 
Strategie, um die Krankheit zu bekämpfen. 
Die erste in Ghana durchgeführte landesweite Suche nach BU Patienten im Jahre 1999 hat das 
Offin-Flussgebiet als eines der Gebiete in Ghana identifiziert, in dem BU am häufigsten auftritt. 
Aufgrund von jüngsten Einzelberichten, die andeuten, dass das Auftreten von Infektionen durch 
M. ulcerans entlang des Flusslaufs schwankend ist, haben wir im Rahmen dieser Doktorarbeit, 
eine umfassende aktive Suche nach BU Patienten und eine Haushaltserhebung in 13 
ausgewählten Gemeinden entlang des Flusses durchgeführt. Dabei konnten wir einen 
allgemeinen Rückgang der BU Prävalenz verzeichnen. Nachfolgend haben wir ein aktives 
Überwachungssystem etabliert, das uns ermöglicht, das Auftreten von Fällen auf Haushaltsebene 
kontinuierlich zu verfolgen. Mit Hilfe dieses Systems konnten wir zeigen, dass eine kombinierte 
Bekämpfung von mehreren vernachlässigten Tropenkrankheiten wie zum Beispiel Lepra und 
Yaws möglich ist und weiterverfolgt werden sollte, um die begrenzten Mittel, die für die 
Bekämpfung dieser vernachlässigten Krankheiten zur Verfügung stehen bestmöglich 
einzusetzen. 
Bis heute konnten Infektionsquellen und/oder mögliche Überträger des Erregers insbesondere in 
BU endemischen Gebieten Afrikas nicht vollständig identifiziert werden. Im Verlauf dieser 
Arbeit haben wir sero-epidemiologische Studien in Ghana und Kamerun durchgeführt, indem wir 
Antikörper-Antworten gegen ein M. ulcerans-spezifisches Antigen gemessen haben, um 
Rückschlüsse auf die Exposition von Bevölkerungsgruppen gegenüber dem Erreger ziehen zu 
können. Dabei haben wir festgestellt, dass Kinder ab einem Alter von etwa vier Jahren, die 
langsam beginnen sich freier zu bewegen und vermehrt Berührungspunkte mit der Umwelt 
haben, erstmals mit M. ulcerans in Kontakt kommen. Beim Vergleich des Alters in dem erste 
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Immunantworten gegen M. ulcerans und gegen andere Krankheitserreger mit unterschiedlichen 
Übertragungswegen einsetzen, haben wir festgestellt, dass serologische Reaktionen auf Antigene 
des von Mücken übertragenen Malaria-Erregers Plasmodium falciparum und der durch Kontakt 
mit verseuchter Erde übertragenen Strongyloides Würmer, früher einsetzt. Im Gegensatz dazu, 
zeigte sich dass die Immunantwort gegen Antigene der durch verseuchtes Wasser übertragenen 
Schistosoma Würmer - wie für M. ulcerans beobachtet - erst später einsetzt. Unsere Daten 
weisen darauf hin, dass die Übertragung von M. ulcerans durch Kontakt mit Umweltquellen des 
Erregers ausserhalb des kleinen Bewegungsbereichs von sehr jungen Kindern stattfindet.  
In den vergangenen Jahren wurde allgemein angenommen, dass die Infektionsquelle von M. 
ulcerans geografisch relativ fixiert ist, da Ausbrüche der Krankheit typischerweise extrem fokal 
auftreten. In diesem Zusammenhang, wurde auch berichtet, dass eine enge Verbindung zwischen 
Genotyp und geografischer Herkunft der klinischen M. ulcerans Isolate besteht. Wir haben die 
Genomsequenzen einer begrenzten Anzahl von klinischen M. ulcerans Stämmen, die von 
Bewohnern des Offin-Flussgebiets isoliert wurden verglichen und zwei gleichzeitig 
vorkommende klonale Komplexe, die weder zeitlich noch räumlich voneinander getrennt waren, 
detektiert. Wir schliessen daraus, dass die Infektionsquelle von M. ulcerans mobiler zu sein 
scheint, als bisher angenommen.  
Da die Herkunft und Übertragungswege von M. ulcerans unklar sind und bis heute kein 
Impfstoff verfügbar ist, wird BU weniger durch Prävention, als vielmehr durch die adäquate 
Behandlung von Patienten bekämpft. Bis heute ist Rifampicin das einzig wirksame Medikament 
gegen BU. Rifampicin-Hepatitis ist jedoch eine häufig auftretende Nebenwirkung, die dafür   
bekannt ist, dass sie in Tuberkulose Patienten, die mit dem Hepatitis B Virus (HBV) infiziert 
sind, sich noch schwerwiegender auswirkt. Wir haben die Krankheitslast durch HBV im BU-
endemischen Offin-Flussgebiet erfasst, indem wir getestet haben, ob Blutseren der allgemeinen 
Bevölkerung das Hepatitis B Oberflächenantigen (HBsAg) enthalten. Die Gesamtprävalenz des 
HBsAg in den Seren war mit 8% hoch. Eine Unterteilung in Altersgruppen hat gezeigt, dass 
Kinder unter 12 Jahren mit einer 1.8% HBsAg-Rate vergleichsweise weniger betroffen waren als 
Studienteilnehmer über 12 Jahren, die eine HBsAg-Rate von 11.1% aufwiesen. Mit Hilfe von 
phylogenetischen Analysen, die auf der Sequenzanalyse der sogenannten pre-S/S Region des 
HBV basierten, konnten wir alle Isolate aus dem Offin Flussgebiet als Genotyp E und Serotyp 
ayw4 klassifizieren. Zudem konnten wir zwei primäre HBV/E Komplexe identifizieren. Während 
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ein Komplex ausschliesslich Stämme aus dem Offin Flussgebiet beinhaltete, setzte sich der 
zweite Komplex nicht nur aus Offin Stämmen, sondern auch aus Isolaten aus anderen Teilen 
Ghanas und West Afrikas, wie zum Beispiel Niger, Nigeria und Benin zusammen. Unsere 
Schlussfolgerung ist, dass die Übertragung des HBV entlang des Flusslaufes primär auf 
horizontalem Weg erfolgt und wir empfehlen daher eine strikte Einhaltung der 
Impfempfehlungen und eine regelmässige Untersuchung der Bewohner des Flussgebiets. 
Zusammengefasst, hat der multidisziplinäre Ansatz dieser Doktorarbeit, der die Untersuchung 
verschiedener Aspekte der Übertragung und Epidemiologie von M. ulcerans zum Ziel hatte, 
wichtige Erkenntnisse geliefert, die massgeblich das schon vorhandenen Wissen über den 
Erreger in Ghana und auch weltweit erweitern.  
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1.1 History and Epidemiology 
In an account of his expedition to identify the source of the Nile river, James Grant described a 
swelling that developed on his right leg in 1861. He reported his lesion as discharging profusely, 
evolving into an ulcer which healed slowly but left him with residual scars and contractures. 
These descriptions are considered to be consistent with the edematous form of BU. Later in 
1897, Sir Albert Cook described cases of what was initially thought to be tubercular ulcerations 
in Kampala Hospital in Uganda. The same hospital in 1910 also recorded a case with an 
ulcerated septic leg and a swelling which was also consistent with the edematous form of BU. In 
1940, a two year old boy with ulcers on his leg was admitted to a hospital in Bairnsdale, 
Australia. Examination of a biopsy sampled from his lesion revealed histological features that 
were not befitting classical tuberculosis. This led to a further probe and based on these features 
being consistently observed in five other patients, the first definitive clinical description of the 
disease, which was later locally referred to as Bairnsdale ulcer [1], was published in 1948 [2]. 
Around the same period, hundreds of similar ulcers were reported from Africa with the majority 
coming from the then Belgian Congo (now Democratic republic of Congo) and Uganda. 
However it was not until the late 1950s and 1960s that the cases were published. Most cases by 
then were reported from the Buruli county of the then Mengo district in Uganda which led 
investigators to refer to the disease as Buruli ulcer [3]. The first probable case identified in 
Ghana was in the year 1971 [4]. By the 1980‟s several endemic foci were reported in many 
countries with West Africa recording the majority of cases [5–8]. By 1998, BU had become a 
global concern and Ghana as an example had recorded nearly 1,200 cases in four of its ten 
regions after a 5 year surveillance. In the same year the World Health Organization (WHO) 
launched the Global Buruli Ulcer Initiative (GBUI) to promote awareness and research efforts on 
the disease. As shown in Figure 1, by the year 2012, BU has been reported or suspected in at 
least 32 countries with Ghana recording an overall national prevalence of 20.7 per 100,000 
population in the first nation-wide active case search in 2002 [9]. 
Equal rates of BU have been reported for both males and females [9–13]. The disease affects all 
age groups but the majority of cases in Africa has been recorded in children with a peak of 
incidence in the 10 to 14 year olds [11,14–20], whereas in Australia adults older than 60 years 
have accounted for most cases [21]. However by adjusting for population age structure, recent 
studies in Africa have shown a bimodal age-related risk of developing BU with the highest risk 
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in children aged between 4 and 14 years and in the elderly [22,23]. As reviewed [24], reported 
risk factors for the disease have varied from study to study although consistently, residence or 
activities within or near slow moving water bodies have been identified by most studies. Thus it 
appears the epidemiology and risk factors associated with occurrence of BU are geographical 
setting-specific, which speaks for the need for studies aimed at understanding these factors for 
individual BU endemic areas 
 
 
 
 Figure 1.1. Distribution of BU worldwide by the year 2012. Map adapted from the W.H.O 
 http://www.who.int/buruli/Buruli_2012_global.png?ua=1 
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1.2 Causative agent 
The pathogen that causes BU is Mycobacterium ulcerans and taxonomically, is a member of the 
phylum actinobacteria, in the order actinomycetales, suborder corynebacteriaceae and the genus 
mycobacterium. It has a high G+C content (65%) DNA and an unusual cell wall with a lipid-rich 
layer beyond the peptodiglycan layer. Due to its long generation time, which has been estimated 
to be around 20 hours; it is described as slow-growing mycobacterium and the optimum growth 
temperature is between 30 and 33°C at pH of 5.4-7.4. Though the pathogen is usually cultivated 
under aerobic conditions it has been reported to grow better under micro-aerophillic conditions 
in liquid cultures.[25]. Genome comparison of M. ulcerans and the fish pathogen Mycobacterium 
marinum revealed a close genetic identity (>97% nucleotide identity) between both pathogens 
indicating a close genetic relationship [26–28]. However, the genome of M. ulcerans was shown 
to harbor a 174kb plasmid, the pMUM001 which is absent in M. marinum, indicating that the 
acquisition of this plasmid was a key event in the evolution of M. ulcerans and was most likely  
by horizontal gene transfer [29,30]. The plasmid encodes the polyketide synthases which 
produce mycolactone, a macrolide toxin at the core of the pathogenesis of M. ulcerans infection.  
Through whole genome sequencing of the first ever complete genome of M. ulcerans, strain 
Agy99 isolated from a Ghanaian BU patient, a more detailed look at the evolutionary scenario 
was made possible [31]. The genome size of M .ulcerans is approximately 5.8 Mb, compared to 
that of M. marinum which is approximately 6.6 Mb. This extensive reduction in genome size is 
indicative of an adaptation to a protected niche environment, where genes formerly needed for 
survival under diverse conditions are no longer necessary. However, it is not clear to date, to 
which environmental niche M. ulcerans is adapting to, although an adaptation within the aquatic 
ecosystem is very likely. Detailed genome analyses of M. ulcerans isolates of patients from 
diverse geographical origin revealed extensive large sequence polymorphisms, facilitating a 
differentiation of M. ulcerans clinical isolates into two principal lineages named the ancestral 
and the classical lineage. While ancestral lineage strains are closely related to M. marinum and 
are only sporadically reported to cause disease in Asia and the Americas, classical lineage strains 
are associated with highly endemic BU foci in Africa and Australia. The reduction in copy 
numbers of genes encoding highly immunogenic proteins particularly in classical lineage strains 
suggests the need for M. ulcerans to evade the immune system of its new host [32]. Altogether, 
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M. ulcerans seems to be evolving from being an environmental pathogen and clues from 
genomic analysis indicate its preparing itself to be better adapted to a new niche environment. 
 
1.3 Reservoir and transmission 
Unlike tuberculosis and leprosy, person to person transmission of BU is very unlikely. 
Epidemiological association and occurrence of BU along slow moving and stagnant water bodies 
led to the hypothesis that transmission involves a reservoir in the aquatic ecosystem [33–36], 
from which humans are being infected via skin abrasions or through insect bites. However, 
several attempts at cultivating the bacteria from a myriad of environmental samples have proven 
futile with only one isolate in pure culture characterized so far [36]. In view of this, 
environmental studies aimed at understanding the ecology of M. ulcerans relied on the detection 
of M. ulcerans DNA by IS2404 PCR as evidence of the bacteria in the environment [35,37–41]. 
The use of IS2404 PCR in the analysis of environmental samples was complicated by the 
discovery that some other mycobacteria do possess this target. [42–44]. This necessitated the 
development of two multiplex real-time PCR assays targeting distinct repeated sequences in the 
M ulcerans genome [45] and the giant plasmid. The target sequences which included IS2404, 
IS2606 and genes encoding the ketoreductase B domain of the mycolactone polyketide 
synthases, have provided a more specific and robust interpretation of environmental data over the 
years.  
Some studies have shown that within the aquatic environment, M. ulcerans could be 
concentrated through the various feeding levels with predacious aquatic insects [38,46,47], fishes 
and amphibians [37,48] identified as potential reservoirs. In Australia, M. ulcerans DNA was 
detected in almost half of possum feces excreted into the environment; a significant proportion 
(41%) of which were detected in the BU endemic Point Lonsdale when compared to 1% detected 
in other non-endemic areas. This led to the implication of possums as potential reservoirs of the 
pathogen in this endemic setting [49]. However, to date, no similar animal reservoir has been 
found in African BU endemic areas [50], it is hypothesized that BU patients with chronic 
ulcerative lesions may play an active role in the dissemination of M. ulcerans in the environment 
in these settings [51]. During an outbreak of BU in Victoria (Australia), investigations lead to the 
capture of more than 11,000 mosquitoes of four different species which were pooled into 957 
groups. A total of 13 pools out of the 957 were positive for M. ulcerans DNA based on real-time 
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PCR probe for all three targets suggesting that adult mosquitoes may serve as biological vectors 
of the pathogen [52]. Findings of some studies have however contested the role of mosquitoes in 
the transmission of the pathogen. One study demonstrated that while M. ulcerans DNA could be 
detected in larvae after feeding in an experimental model, the bacteria were not maintained 
through pupation and development into adult mosquito. Additionally, external body parts of 
adult mosquitoes were readily contaminated with the bacteria while feeding, whereas the guts 
lacked detectable M. ulcerans DNA [53]. A more recent field study conducted in Benin also 
failed to detect M. ulcerans DNA in a total of 7,230 flying insects which included 4,322 
mosquitoes from 10 different species captured over a year [54]. Finally, analysis of the 
anatomical distribution of BU lesions in laboratory confirmed cases from Cameroon revealed 
patterns which were inconsistent with mosquito bites [23].  
Taken together, these findings suggest that several modes of transmission of M. ulcerans should 
be considered. 
 
1.4 Pathogenesis and immune response to M. ulcerans infection  
Initial suspicion of a toxin-mediated pathogenesis of M. ulcerans infection was deduced from 
histological examination of biopsies of index patients from Australia which revealed copious 
amounts of bacilli clumped within a large necrotic core [2]. The toxin, later named mycolactone 
[55], has been shown to induce apoptosis and necrosis of many cell types including fibroblasts, 
leukocytes and adipocytes [56–59]. Within in-vitro models, the toxin was shown to inhibit the 
phagocytosis of the bacteria by macrophages [56,57,60,61]. In view of this, M. ulcerans was 
largely considered to be an extracellular pathogen with mycolactone being the key virulence 
factor.  
These histological features which were consistently observed in biopsies of patients over the 
years are now known to be characteristic for late stage M. ulcerans infection. During the early 
phase of M. ulcerans infection, colonization of macrophages and to lesser extent neutrophils by 
the bacteria has been shown in studies of mouse [58,62] and guinea pig [63] infection models as 
well as in biopsies of untreated BU patients [62,64]. These observations corroborate several 
studies that highlight cell-mediated immune response to M. ulcerans. As reviewed elsewhere 
[65], delayed-type hypersensitivity response to the burulin skin test has been reported frequently 
in patients with advanced or healed lesions but rarely in patients with early staged lesions. In 
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addition, PBMC‟s from BU patients have demonstrated a significantly higher production of IFN-
γ in later stages of the disease than in the early stages [66,67]. Expression of IFN-γ was also 
shown to be higher in pre-ulcerative lesions than in the ulcerative forms by quantitative PCR 
[68]. These data also indicate that protective immunity to M. ulcerans by Th1 response is 
possible. 
In addition to cell mediated immunity, sero-epidemiological studies have demonstrated that 
individuals can mount specific humoral immune response to M. ulcerans infection. While 
investigations of humoral immune responses against mycobacteria are usually hampered by a 
high degree of antigenic cross-reactivity between species, investigations on exposure of 
populations to M. ulcerans were made possible by the identification and characterization of the 
18 kDa small heat shock protein overexpressed by the pathogen [69,70].  
 
1.5 Clinical presentation and Diagnosis 
Typically within endemic settings in Africa, initial clinical manifestation of the disease is a firm 
painless nodule. Other pre-ulcerative presentations are edema, plaque and papule. While edema 
represents the most extensive pre-ulcerative form with ill-defined margins, papules are less than 
a centimeter in size and are commonly reported in Australia but absent in Africa. Plaques on the 
other hand have irregular edges and are more present in Africa but absent in Australia. When left 
untreated for some weeks, the pre-ulcerative forms progress to ulcers which are characterized by 
an eroded skin surface with well demarcated margins and undermined edges. The list of 
differential diagnosis is endless in tropical settings, where other skin conditions such as 
sebaceous cyst, cutaneous tuberculosis, leprosy, yaws, lipoma, cutaneous leishmaniasis, tinea, 
noma etc. resemble disease caused by M. ulcerans [71–73]. Diagnosis of BU was mainly based 
on clinical evidence until 2001 when the WHO recommended the inclusion of laboratory 
diagnostic tests in the confirmation of BU cases. Available tests are microscopic detection of 
Acid Fast Bacilli (AFB) in a Ziehl-Neelsen (ZN) stained smear, M. ulcerans culture, detection of 
M. ulcerans DNA by IS2404 PCR and histopathological analysis of skin sections. The ZN test 
which is already being employed at the district level for the diagnosis of TB has a very low 
sensitivity [74] and is also not specific for M. ulcerans. Culture takes an average of nine to 
twelve weeks to yield positive results making it an unfavorable option for timely diagnosis and 
treatment. Despite having high sensitivity and specificity, the IS2404 PCR and histopathological 
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analysis require sophisticated instrumentation and skilled operator (personnel); thereby 
restricting their availability and operation to reference laboratories [75–79]. Currently, a total of 
17 reference laboratories assist the control programs of 10 countries with the confirmation of BU 
mainly by IS2404 PCR [80]. 
Nevertheless, BU cases are still being diagnosed solely on clinical presentation at the periphery 
of endemic countries in Africa. Research aimed at developing a simple point-of-care (POC) 
diagnostic tool has gained a lot of attention. One of such tools is the loop-mediated isothermal 
amplification (LAMP) which like the IS2404 PCR, is also based on the amplification of M. 
ulcerans DNA but under isothermal conditions [81–83] . It is worth noting that the LAMP assay 
doesn‟t require purified M. ulcerans DNA thereby cutting away time, cost and skill required for 
DNA isolation. In addition, higher specificity is achieved with the assay by using four to six 
specifically designed primers targeting different sections of the DNA sequence. Another property 
of M. ulcerans infection that has been exploited for POC assays is the ability of mycolactone to 
diffuse beyond infection foci, making it detectable in circulating blood [84]. Previous studies 
have demonstrated that detection of Mycolactone A/B by conventional thin-layer 
chromatography (TLC) is possible; however a minimum of 20 to 30ng concentration of the lipid 
is required [84–86]. An investigation conducted to address this draw-back lead to discovery that 
reaction of mycolactone with 2-napthylboronic acid in a TLC flourogenic model lowers the 
detection limit of mycolactones from 20ng to 10ng [87]. The assay has been studied in the mouse 
foot pad model [75] and is currently being further evaluated within a clinical trial setting. 
Another noteworthy approach is the antigen capture assay which was motivated by the 
identification and characterization of the M. ulcerans protein MUL_3720 [89]. The protein, 
which has no orthologue in other prevalent pathogenic mycobacteria, is abundantly expressed 
and localized within the cell walls of M. ulcerans. This makes it a favorable candidate for 
different assay formats since the absence of orthologues in other mycobacteria will enhance its 
specificity and the localization within the cell wall makes it more accessible in diagnostic 
samples such as swabs. Work is on-going to enhance the sensitivity of this assay. 
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Figure 1.2. Laboratory diagnosis of BU. 2A Detection of M. ulcerans DNA in clinical samples 
by IS2404 PCR. 2B Cultivation of M. ulcerans on LJ media. 2C Microscopic detection of Acid 
fast bacilli (AFB) in a ZN stained smear. 2A and 2B were adapted from W.H.O 
http://www.who.int/buruli/photos/diagnosis/en/ 
Chapter 1 – Introduction 
 
10 
 
1.6 Treatment and case management 
Although the search for anti-mycobacterial agents for M. ulcerans dates as far back as the 1950‟s 
[90,91], the mainstay treatment of BU for decades was surgical excision of necrotic tissue and 
skin grafting for very large lesions. As it was with clinical diagnosis, treatment success depended 
highly on the expertise of the surgeon and recurrence rates between 6-28% were reported during 
this period [92–95]. Based on the activity of anti-mycobacterial agents in a mouse model [96] 
and a successful clinical trial in Ghana [97], the WHO in 2004 recommended a standard 
treatment of injectable streptomycin (STR) and oral rifampicin (RIF) for 8 weeks. Most control 
programs have implemented this regimen till date with diminished recurrence rates of 0-2% and 
surgery being employed mainly for correction of functional disabilities [97–99]. Concerns over 
challenges with general application of STR such as loss of hearing (side effect) [100], intra-
muscular administration to very young children and contraindication in pregnancy, led to the 
search for an all oral alternative. Some recent studies have demonstrated that substitution of STR 
with clarithromycin (CL) is equally efficacious in any of following combinations; RIF and CL 
for 8 weeks [101], RIF and STR for two weeks followed by RIF and CL for six weeks [102] or 
RIF and STR for four weeks followed by RIF and CL for four weeks [103]. Therapeutic 
application of heat (of about 40˚C) on BU lesions (thermotherapy) also represents an alternative 
treatment approach. By exploiting the inability of M. ulcerans to proliferate well above 37˚C 
[104], heat applied to lesions over a period of time have resulted in the successful treatment of 
some BU cases [105–107]. Although considered by the WHO as a viable alternative [108], 
thermotherapy is yet to be incorporated into the general treatment practice for BU. 
Even with successfully treated cases, scarring deformities (cosmetic and functional) were notably 
associated with BU until 2006 when the WHO made a focal commitment to the prevention of 
disability [109]. This has resulted in the incorporation of physiotherapy in the treatment package 
offered to BU cases. In Ghana, well-equipped physiotherapy units have been established in 
health centers like Nkawie Government Hospital and Agogo Presbyterian Hospital of the Ashanti 
Region. 
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Figure 1.3. Clinical presentation of BU. 3A Nodule 3B Edema 3C Plaque 3D Ulcer 
        Images adapted from W.H.O http://www.who.int/buruli/photos/forms_large/en/ 
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1.7 Control and prospects for a vaccine 
With the mode of transmission of M. ulcerans not fully elucidated, the main approach to control 
has been early case detection and treatment to prevent deforming sequelae. In line with this, 
Buruli ulcer control programs have been established in more than 10 countries worldwide. The 
control programs usually operate within the framework of the National Health Service. In 
countries like Cameroon, BU control is integrated into that of leprosy, yaws and leishmaniasis to 
maximize the limited resources allocated for the control of these diseases. In Ghana, non-
governmental initiatives such as Stop Buruli which is funded by the UBS Optimus Foundation 
provide support with active case search, transportation of patients to and from the health 
facilities as well as providing breakfast throughout the treatment period. This social intervention 
strengthened community participation in BU control which reflected in an increase in the number 
of case referrals by volunteers and school teachers in the Ga South district [110]. 
Ideally, vaccination would serve as the best approach to the control of BU in highly endemic 
settings. However, there is no effective vaccine against BU till date. As far back as 1957, the M. 
bovis BCG (Bacille Calmette Guérin) vaccine was shown to confer protection against M. 
ulcerans in a murine footpad model [111]. The vaccine also demonstrated an overall 47% 
efficacy in a randomized control study involving 2,500 refugees living in Uganda. This 
protection was however short-lived, diminishing from 72% to 0% after 6 months [112]. No 
evidence of a protective effect on the risk of developing BU was found in a number of case-
control studies [113–116]. However, a study conducted in Benin reported a significant 
association of effective BCG vaccination at birth with protection against the osteomyelitic form 
of BU in both children and adults [19]. The evidence of a cross-reactive protective role of BCG 
vaccines and investigations into the underlying mechanisms led to the identification and 
characterization of the M. ulcerans homologue of the BCG antigen (Ag) 85A. Earlier 
experiments demonstrated that mice immunized with DNA vaccines encoding Ag85A of BCG 
vaccines were protected from intradermal challenge with M. ulcerans [117]. As expected, DNA 
vaccine encoding Ag85A from M. ulcerans demonstrated a higher protective efficacy than that 
encoding Ag85A from BCG when both were compared in an M. ulcerans footpad model [118]. 
An alternative vaccine strategy involves the use of a viral replicon particle as an apparatus for 
delivering M. ulcerans antigens to the immune system. The vesicular stomatitis virus (VSV) 
recombinant replicon particle was constructed by replacing the VSV glycoprotein G gene with 
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two M. ulcerans genes, the MUL_2232 and MUL_3720. Immunization of mice with the virus 
replicon particles resulted in a slight but significant decrease in bacterial load in an M. ulcerans 
footpad model [119].  
In spite of the challenges faced in the development of an effective vaccine against BU, the ability 
of humans to mount protective immune response against M. ulcerans as demonstrated by only a 
small proportion of exposed individuals developing the disease eventually [69,120,121] and 
reports of some self-healing cases [122], continue to motivate research in this field. 
 
1.8 Co-morbidity: BU and Hepatitis 
Besides being the only effective antibiotic identified for BU till date, rifampicin is part of the 
five “first-line” antibiotic therapy for tuberculosis. As far back as 1972, a high proportion of 
patients being treated for tuberculosis were reported to develop abnormal liver function test 
(LFTs) and histological features suggestive of hepatitis. This led to the first clinical description 
of what was termed “Rifampicin hepatitis” in 1974 [123]. The report indicated that 10 out of 11 
patients developed the symptoms within six weeks of starting rifampicin therapy. 
Incidence of this condition, also known as drug-induced hepatotoxicity (DIH) has been reported 
in the management of other diseases like Pruritus where rifampicin is administered [124,125]. 
Although overt liver damage from rifampicin is rare, some studies have reported that pre-existing 
liver damage resulting from Hepatitis B virus (HBV) infection for example, could be aggravated 
[126,127]. Specifically for tuberculosis patients undergoing chemotherapy, a higher incidence of 
hepatotoxicity has been observed in those pre-infected with HBV (both carriers and diseased) 
than controls although the sole effect of rifampicin was debated in some reports [128–132]. 
While some studies indicate that HBV infection is highly endemic in sub-Saharan Africa, the 
exact burden of the disease in most countries is unknown [133]. Particularly in rural areas where 
other diseases like BU are also suspected to be present and underreported, co-endemicity of both 
diseases presents a complex challenge to clinicians. 
It is also of Public Health importance that transmission of hepatitis particularly in BU endemic 
areas is monitored closely in order to better inform control strategies for both diseases. 
Furthermore, the availability of a free and effective vaccine against Hepatitis B necessitates 
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studies which monitor the efficiency of the vaccination program and the burden of the disease in 
such endemic regions. 
The sixth chapter of this study assesses the burden of Hepatitis B and Delta virus infection within 
the BU endemic region of the Offin river valley and highlights some findings relevant for the 
control of the disease both within the study area as well as nationwide. 
 
1.9 Goal 
This PhD study was set up to investigate the epidemiology of BU in communities along the Offin 
river valley of Ghana within the context of the under-listed objectives. We anticipate that 
findings of this thesis will contribute to the knowledge of transmission of M. ulcerans within the 
river basin as well as in Ghana. 
 
1.10 Objectives 
1. To characterize the epidemiology of BU in 13 selected communities along the Offin river 
2. To assess the age of sero-conversion to the M. ulcerans 18kDa shsp as a reflection of the 
onset of exposure to M. ulcerans 
3. To compare the age-pattern of first humoral immune responses to the 18kDa shsp of M. 
ulcerans with those against pathogens with different modes of transmission  
4. To study the dynamic population structure of M. ulcerans by whole genome sequencing 
and analysis of the bacteria isolated from cases residing within the Offin river basin 
5. To study the prevalence of Hepatitis B and D virus infection and characterize the genetic 
diversity of the virus within the river the basin 
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2.1 Abstract 
Buruli ulcer (BU) is a neglected tropical skin disease caused by Mycobacterium ulcerans with 
more than two thirds of the global cases reported in West Africa. A nationwide active BU case 
search conducted in 1999 identified two health districts along the Offin River as two of the three 
most endemic districts in Ghana. Based on recent anecdotal accounts that transmission is 
unstable along the Offin River, we conducted from March to June 2013 an exhaustive household 
survey and active case search in 13 selected communities within a five-kilometer radius along 
the Offin River. The overall prevalence of BU was 2.3% among the surveyed population of 
20,390 inhabitants and 477 of the total 480 cases detected (99.4%) were historical (healed) cases. 
By estimating the year of occurrence for each case per community and taking into account 
available passive surveillance records of health facilities and the District Health Directorate, we 
observed a general trend of continuous emergence of cases in communities located midstream 
the Offin River whereas downstream communities showed more sporadic patterns. We 
monitored the incidence of cases after the survey and recorded a cumulative incidence rate of 
0.04%  for the 13 communities over a 17-month active surveillance period from August 2013 to 
December 2014. Our data reveal an overall decline in BU incidence along the Offin River similar 
to the general decline in BU incidence in recent years reported by the World Health Organization 
for West Africa. 
 
Keywords: Buruli ulcer, Prevalence, Incidence, Active surveillance, Ghana, Offin River  
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2.2 Author summary 
Buruli ulcer (BU) is a tropical skin disease caused by Mycobacterium ulcerans and more than 
two thirds of the global cases reported in West Africa. The Offin has been considered the most 
endemic river valley in Ghana following a nationwide active case search conducted in 1999. 
Here, we present findings of an exhaustive household survey and case search of 13 selected 
communities along the Offin river aimed at addressing recent anecdotal accounts of unstable 
transmission of M. ulcerans within the river basin. We observed among the surveyed population 
of 20,390 inhabitants, an overall 2.3% prevalence of BU with 99.4% of the total cases detected 
being historical cases. We also observed a general trend of continuous and sporadic emergence 
of cases in mid and downstream communities, respectively. Subsequently, we detected a total of 
eight cases (0.04% cumulative incidence rate) in a prospective 17-month active surveillance of 
all 13 communities. These data confirm the recent decline in BU incidence in historically 
endemic communities along the Offin river basin, analogous to the observation made in recent 
years by the World Health Organization for West Africa.  
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2.3 Introduction 
Buruli ulcer (BU) is a necrotizing skin disease caused by Mycobacterium ulcerans [1]. The 
disease has been reported in over 30 countries worldwide, mainly in the tropics, but the brunt of 
it seems to be mainly experienced in West Africa with Côte d‟Ivoire, Ghana, Benin and 
Cameroon reporting more than 80% of the global number of cases [2]. Within the endemic 
countries, BU occurs in foci typically affecting inhabitants of impoverished and rural settings 
where access to medical care is a big challenge [3]. 
Control of BU is based mainly on early case detection and adequate antibiotic treatment and 
wound management. The current treatment regimen recommended by the World Health 
Organization (WHO) includes daily administration of streptomycin and rifampicin for eight 
weeks [4]. Advanced lesions may require debridement and/or skin grafting as an adjunct to 
improve healing and to prevent or correct deformities [5–7]. Nevertheless BU treatment is often 
associated with long hospital stays and represents a major socio-economic burden in the affected 
communities [8].  
In Ghana, nearly 1,200 BU cases were reported between 1993 and 1998 by the first passive 
surveillance system established in the country and between 2004 and 2014 more than 9,000 cases 
have been reported. A nation-wide active case search conducted in 1999 resulted in an overall 
crude prevalence rate (clinically diagnosed active lesions) of 20.7 per 100,000 inhabitants [9]. 
The most endemic district identified within this study was the Amansie West District, which is 
drained by the Offin river. The river takes its source from the Mampong scarp in the Ashanti 
region, flows from Boanim community through Bipoa community and eventually joins the Pra 
river in the Central Region (Fig 2.1). With farming and alluvial gold mining being the 
characteristic human activities in the river basin, spatio-epidemiological studies have 
consistently associated these activities with BU [10,11]. 
From June to July 2012, we paid reconnaissance visits to all 11 Health Districts drained by the 
Offin River. Anecdotal accounts gathered from interactions with local health staff and leaders of 
some selected communities indicated the absence of recent (in the past 3 to 5 years) cases in 
some communities historically known to be BU endemic and the emergence of new cases in 
some non-endemic communities. Since BU case data at the local and district health facilities 
were scanty, we set up this study with the following specific objectives: i) to determine the 
prevalence of BU in 13 selected communities in the Offin river basin, ii) to characterize the 
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retrospective occurrence of BU cases for each community based on active surveillance data and 
available case data at the district and local health centers. We also report on active surveillance 
activities conducted to prospectively monitor the emergence of new BU cases in the selected 
communities.  
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2.4 Materials and Methods 
Ethics statement  
Ethical clearance for this study was obtained from the institutional review board of the Noguchi 
Memorial Institute for Medical Research, NMIMR, with a federal wide assurance number 
FWA00001824 and the ethics review committee of the Ghana Health Service (ethical approval 
ID number GHS-ERC:06/07/13). Participation in all aspects of the study was voluntary and all 
confirmed cases - independent of their participation- were treated according to the treatment 
guidelines established by the National Buruli Ulcer Control Program (NBUCP). Written 
informed consent was obtained from all patients before their lesions were sampled for laboratory 
diagnosis. Parents or guardians provided written consent on behalf of all child participants. 
 
Study area 
This study was conducted in the Offin river valley of Ghana (Fig 2.1). The Akans, who form the 
largest ethnic group in Ghana, are the main inhabitants of five out of the ten administrative 
regions (Ashanti, Central, Western, Eastern and Brong –Ahafo). The Offin river drains two of 
these regions namely the Ashanti and Central Regions. Due to the intense gold mining activities 
carried out in the river basin, anecdotal accounts suggest that this preponderance breaks down at 
the community level due to the influx of migrants from other parts of Ghana and neighboring 
West African countries.  
Our study area presents major landscape differences between communities located upstream the 
river on one hand, and those located mid and downstream on the other hand. As illustrated in 
Figure 2.2, land cover of upstream communities Bedomase (A) and Krakrom (B) was mainly 
farmland. In contrast, the peripheries of the mid and downstream communities were generally 
characterized by heavy mining activities as exemplified by Ntobroso (C) and the downstream 
community Pokukrom (D). In addition, our assessment of the elevation patterns with respect to 
the Offin river course revealed that the highlands of Mampong in the Ashanti region from which 
the river takes its source were at least 401m (1,315 ft) high (Fig 2.3C). Thus communities A to C 
located upstream the river were situated in areas with altitudes of at least 256m. Conversely, the 
midstream to downstream region of the Offin river recorded relatively lower elevation values 
ranging from 173m to 98m (569-320 ft). 
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Following a nation-wide active BU case search [9], the NBUCP maintained a database of 
geographic co-ordinates of communities visited. We obtained from the NBUCP geographic co-
ordinates of all communities in the 11 health districts of the Offin river valley. Using the ArcGIS 
10.0 mapping software, we created a buffer of five kilometers along the river. This seeded a total 
of 199 communities from which we selected 10 by simple randomization using a randomization 
tool embedded in the software (Fig 2.3A). The selected communities were Bedomase (A) and 
Krakrom (B) of the Sekyere south district, Kapro (C) of the Atwima Nwabiagya district, 
Ntobroso (E) of the Atwima-Mponua district, Keniago (G) and Tontonkrom (H) of the Amansie 
West district, Dominase (I) and Nkotumso (J) of the Upper Denkyira West district, Wromanso 
(K) of the Amansie Central district and Pokukrom (M) of the Upper Denkyira East district (Fig 
2.3A). Based on recommendations of local health staff, three additional communities known to 
be BU endemic were included to bring the total number to 13. These communities were; 
Akomfore (D) and Achiase (F) of the Atwima Mponua district, and Mfantseman (L) of the 
Upper Denkyira East district. Other selected communities known to be endemic based on 
available passive surveillance records were Ntobroso (E), Keniago (G), Tontonkrom (H), 
Dominase (I), Wromanso (K), Pokukrom (M) and Nkotumso (J). Passively, no BU case has ever 
been reported for Bedomase (A) and Krakrom (B). We were unable to substantiate the 
endemicity of Kapro (C) prior to the survey.  
 
Community entry 
Entry into each community was carried out by a team consisting of a research assistant from the 
NMIMR, a field officer from NBUCP, a local disease control officer (DCO) and a community 
based surveillance volunteer (CBSV). We met chiefs, traditional and opinion leaders of each 
community to whom we explained the structure, aims and benefits of the study. Once we 
received their approval, information on the study was relayed to the community members 
through the CBSV and community information delivery systems. 
 
Data collection 
Between February and May 2013, we conducted an exhaustive household survey and active case 
search for BU. We formed teams each consisting of one research assistant from NMIMR, one 
local health staff routinely involved in the management of BU cases and one community 
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volunteer. To aid in the description of the disease to participants being interviewed, each team 
was equipped with posters and picture charts illustrating the clinical forms of BU. Members of 
the teams received training on the clinical signs of BU, how to fill the survey forms and also how 
to take GPS co-ordinates. The teams went out to each inhabitable structure, numbered them 
serially and interviewed all inhabitants who were present. Households of inhabitants who were 
absent were noted and in two follow-up sessions on study participants (July and December 
2013), we interviewed those absentees who were now available. Information on minors was 
provided by their parents or guardians. In addition to demographic data, clinical data were also 
collected for detected cases and GPS co-ordinates for every household. 
 
Definition of variables  
An inhabitant was classified as a part-time resident of a community if in the past year prior to the 
survey the person; a) travelled and stayed out of the community for more than 3 months and b) 
had his livelihood (such as occupation and education) in another community such that he spent 
more than 6 hours of his day-time there. A full-time resident on the other hand a) never travelled 
out of the community in the past year or b) travelled but stayed no longer than 3 months and c) 
had his livelihood in the community being surveyed and thus spent more than 6 hours of his day 
time there.  
Each time we completed surveying a community, we extracted information on inhabitants with 
suspected lesions and revisited them together with a clinician of extensive experience in 
diagnosing BU. The clinician then examined the lesions and diagnosed them as either active or 
inactive (healed) BU or as BU-unrelated lesions. Generally, depressed stellate scars were 
anecdotally considered as healed BU lesions whereas healed lesions with cleared skin areas were 
considered as BU-unrelated. Thus, cases with both active and healed lesions were included in 
this study. Clinically diagnosed active lesions were microbiologically confirmed by the detection 
of M. ulcerans insertion sequence (IS) 2404 by diagnostic PCR. In addition, BU lesions were 
clinically classified according to the WHO guidelines. Category I lesion was defined as a single 
lesion of size less than or equal to five centimeters at the widest diameter, category II as a single 
lesion between five and 15 cm and category III as either a single lesion greater than 15 cm or 
multiple lesions or a lesion at critical areas of the body. 
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Estimation of the year of emergence of BU cases in each community 
Using posters and charts the clinical features of BU was described to the participants after which, 
we asked participants if they have ever had an episode of BU at any point in their lives. This was 
done to determine the overall crude life time prevalence of BU in the population surveyed. 
However, in order to assess the historical emergence of cases for each community, we restricted 
our analysis of the healed cases to a 24 year prevalence period (1990 to 2013) and compared our 
data with passive surveillance records obtained from 2000 to 2013. 
Admittedly, such retrospective analyses are prone to recall bias particularly for BU where the 
appearance of symptoms does not reflect the moment of contracting the disease due to a 
relatively unknown incubation period. For BU cases with healed lesions, we estimated the year 
of developing the symptoms of the disease by i) examining health records and BU 01 forms (if 
available) and ii) verbally interviewing the cases and confirming from at least two other 
household inhabitants or nearby neighbors who were present and witnessed the case having the 
disease. To facilitate recall in healed cases of more than one year history, estimation was done by 
reference to any other household member or close neighbor who was born around the period the 
case developed symptoms of the disease. Once this estimation was confirmed by two other 
inhabitants present at the time of developing the clinical symptoms of BU, the period was 
estimated and noted using the year of birth of the inhabitant referenced. 
 
Active surveillance of BU  
Subsequent to the exhaustive household survey, we continued to monitor the emergence of BU 
cases using two approaches: i) community outreach program and ii) monthly household visits by 
community volunteers. We conducted the community outreach once every three months in all 13 
selected communities. Specifically in the months of July 2013, September 2013, December 2013 
to January 2014, March 2014, July to August 2014 and November 2014.This program involved 
one evening of educating the community members on transmission, early case detection and 
treatment by showing BU documentaries and interacting with them through questions and 
answers. The following morning, the inhabitants were screened and those with clinically 
suspected BU lesions were sampled for laboratory confirmation. 
For seven of the 13 communities (Achiase (F), Ntobroso (E), Akomfore (D), Keniago (G), 
Pokukrom (M), Wromanso (K) and Mfansteman (L)), we employed a monthly household-visit 
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based surveillance as an additional tool to the surveillance by the community outreach program. 
All seven communities were selected based on the willingness of the CBSV to voluntarily carry 
out the exercise. We trained and equipped one CBSV from each of the afore-mentioned 
communities with android phones (HTC wildfire S) pre-loaded with a BU surveillance 
questionnaire. The questionnaire was designed using the Epicollectplus mobile application 
(http://plus.epicollect.net/). From August 2013 to December 2014, the CBSVs were mandated to 
visit all households in a month and record any suspected case using the mobile application and a 
notebook. Suspected cases were then sampled by a local health staff and the samples were sent to 
the NMIMR for laboratory confirmation. We then assessed the feasibility and efficiency of this 
approach by evaluating the number of cases detected, the severity of lesions sampled and the 
community coverage (the proportion of households inventoried during the exhaustive survey that 
could be visited in a month by the volunteer). 
 
Laboratory confirmation of BU cases 
To confirm suspected active BU lesions, two swab specimens were collected from the 
undermined edges of ulcerative lesions. For pre-ulcerative lesions, one fine needle aspirate 
(FNA) was transferred into 500 µl phosphate buffered saline (PBS) as previously described [12] 
and transported to NMIMR at 4˚C. Laboratory confirmation was conducted as previously 
described. Briefly, suspensions from pooled swabs of the same lesion containing 2 ml of PBS 
were concentrated by centrifuging at 3,000 x g for 15 minutes. The supernatant was then 
decanted and the sediment mixed with PBS to make up a final volume of 500 µl suspension from 
which 100 µl was used to prepare slides for Ziehl-Neelsen (ZN) microscopy. From the residual 
400 µl suspension, we extracted M. ulcerans DNA for IS2404 PCR. 
 
Mapping and Data Analysis 
Summary data from household surveys were mapped and analyzed using the ArcMap (Economic 
and Social Research Institute, version 10.0). The elevation values (presented in feet) were 
derived from 15 meter resolution Advanced Spaceborne Thermal Emission and Reflection 
(ASTER) Satellite digital elevation model (DEM) data, obtained at a sun angle of 59.6 degrees. 
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All statistical analyses were carried out using GraphPad Prism version 6.0 (GraphPad Software, 
San Diego California USA) and Stata 12 (Statacorp 2011 statistical software Release 12. College 
Station, TX: StataCorp LP). 
Chapter 2 – BU in the Offin River Basin of Ghana  
 
36 
 
2.5 Results 
Demographic characteristics of the surveyed population 
A total of 2,822 households of three hamlets, seven villages and three peri-urban settings along 
the Offin river were visited to survey the population for BU.  
In all, we surveyed a total population of 20,390 inhabitants, 50.08% (n=10,211) females and 
49.92% (n=10,179) males (Table 2.1). The majority (90.0%) of these inhabitants were full time 
residents. Characteristic of a youthful population, the mean age recorded for the survey was 23.6 
(S.D +/- 18.8) years and 39.7% of the surveyed population below the age of 15 years (Fig 2.4A). 
As expected, in all of the visited communities, the Akans represented the major ethnic group 
(46.9% to 96.5%). 82.8% of the population between the ages of 4 and 18 years were students. 
We observed that miners formed less than 1% of the population we surveyed upstream the river 
(0.4% from Bedomase and none from Krakrom and Kapro). On the other hand, miners were well 
represented in mid and downstream communities like Nkotumso and Tontonkrom where they 
formed the highest and second highest occupational group, respectively.   
 
BU cases identified in the selected communities 
Based on clinical signs and symptoms, we identified seven suspected active BU cases of which 
three were confirmed; one by both ZN and PCR and two by PCR only. All three confirmed cases 
(one male and two females) had ulcerative lesions. The male patient who was 6 years old 
presented with a category I ulcer on his thorax. One 35 year old female presented with category I 
on the upper left limb and the other 22 year old female had a category II ulcer on her lower left 
limb. Based on the clinical assessment of healed lesions by an experienced clinician, we could 
detect a total of 477 cases with healed BU lesions from the 13 communities. Of these 477 healed 
cases, 138 (28.9%) had been previously diagnosed (clinical and/or laboratory) as active BU and 
noted in existing passive surveillance records. We estimated 0.01% and 2.34% prevalence of 
active and healed BU cases respectively in the surveyed population. We observed no significant 
difference (P=0.12) between the proportion of historical cases in females (2.6%, 266/10209) 
when compared to the proportion recorded for males (2.0%, 211/10178). The age of the 477  
healed cases identified during the survey at the estimated onset of the disease ranged from 0.75 
to 87 years with a mean age of 31 years (SD=18). Children under 15 years accounted for 48.1% 
of the total number of cases. When we computed the age adjusted prevalence based on the age 
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distribution of the population surveyed, we observed the highest peak for children between 10 
and 12 years (Fig 2.4B). 
 
Emergence of BU cases in the community and distribution of burden along the Offin river 
The BU prevalence for all surveyed communities is listed in Table 2.1. The disease burden was 
not uniform along the river. By grouping all 13 study communities according to their location 
along the Offin river, we observed that BU cases detected formed 0.1% (2 out of 2,491) of the 
total population surveyed upstream the river (communities A to C). This was significantly 
smaller (P<0.001) than the proportion recorded for communities D to H located mid-stream 
(2.4%, 274/11,160) and I to M located down-stream the river (3.0%, 204/6,739). As illustrated in 
Fig 2.3B, upstream, we detected no case in Bedomase (A) but recorded a prevalence of 0.90% 
and 0.14% in Krakrom (B) and Kapro (C), respectively. Prevalence was higher midstream 
(between 1.22% and 3.89%). The highest overall prevalence (8.9%) was recorded downstream 
the river in the Mfantseman (L) community. In the other downstream communities we recorded a 
prevalence of 2.46%, 3.61%, 2.31% and 1.33% for Dominase (I), Nkotumso (J), Wromanso (K) 
and Pokukrom (M), respectively.  
Based on the BU history data compiled for all 480 cases detected during the active case survey 
(ACS), we estimated the time span during which cases emerged for each community included in 
the survey. In a second step, we compared our results with the annual passive case surveillance 
(PCS) data available at the local and district health centers. We estimated a population growth 
rate of 3.8% per annum for communities A to H of the Ashanti region and 3.2% per annum for 
communities I to M of the Central region using data from the regional populat ion census 
conducted in 2000 and 2010. The annual BU case estimates for both ACS and PCS were 
expressed per 1,000 inhabitants to facilitate the comparison of trends between communities (Fig 
2.5 and Fig 2.6). 
While PCS data prior to the year 2000 was not available for any of the 13 communities surveyed, 
our annual ACS trend corroborated reasonably well with PCS data available for the years later 
than 2000. Altogether, we observed slightly differing trends in BU case emergence for upstream 
and downstream communities. The most upstream-localized community Bedomase (A) was non-
endemic, as no case has ever been detected by PCS or ACS. In upstream communities Krakrom 
(B) and Kapro (C), we identified only one index case each corresponding to nine cases per 1,000 
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inhabitants and one case per 1,000 inhabitants respectively. While no PCS data was available for 
both cases detected, the cases were estimated to have emerged in 2009 and 2005 for Krakrom 
(B) and Kapro (C) respectively. Among all the mid-stream communities (D-H), we observed a 
continuous emergence of BU cases with at least one case per 1,000 inhabitants being recorded 
each year by either ACS or PCS or both from 2000 to 2014 (Fig 2.5). The downstream 
communities (I to M) which incidentally represent communities located within the Central region 
were generally characterized by a less continuous trend (Fig 2.6). For the historically endemic 
community Nkotumso (J), we observed an absence of cases from 2010 to 2014 after a long 
period of rather consistent emergence of cases. The further downstream communities Wromanso 
(K) and Mfansteman (L) were characterized by sporadic emergence of cases. Additionally, the 
highest number of cases per 1,000 inhabitants for a single year (25 cases in 2011) was observed 
in Wromanso (K). 
In all, 95.8% (460/480) of the total BU cases detected have resided in their respective 
communities for more than three months. Additionally, when we stratified the population 
surveyed by their length of stay in the communities, we observed that BU cases made up 3.2% 
(460/14,332) of the group with more than three months of residence. This was significantly 
higher (P<0.001) when compared to the proportion recorded for those who have resided for three 
months or less (0.6%, 20/3613). 
 
Active BU surveillance 
By employing both community outreach and household-visit surveillance, we continued to 
monitor the emergence of BU cases in all 13 selected communities over the 17-month period 
from August 2013 to December 2014. In all, we detected 29 clinically suspected BU cases 
during this active surveillance period. Five of these cases were detected through the community 
outreach program (four from Ntobroso and one from Dominase) and 24 were detected through 
the monthly household visits. Eight of them (27.6%) were laboratory confirmed by IS2404 PCR. 
As expected for an active surveillance activity, all eight cases (five males and three females aged 
between 3 and 35 years, with a mean age of 18 (SD=9))) had lesions in their early stages; five 
were detected with pre-ulcerative lesions (four nodules and one plaque) and three presented with 
Category II ulcers. The 21 non-confirmed suspected BU cases were referred to the district 
hospital for further assessment and alternative diagnosis. 
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The monthly household visits resulted in the detection of seven out of the eight laboratory 
confirmed cases. All seven cases were detected in three communities: Achiase (four cases), 
Ntobroso (two cases) and Akomfore (one case).Laboratory case confirmation rate for Achiase (4 
out of 6 (66.7%)) was significantly higher (P=0.03) than the combined rate recorded for all other 
communities (4 out of 23 (17.4%)).  As shown in Fig 2.7, all four cases from Achiase were 
detected in months when the volunteer had covered more than 50% of the households.  
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2.6 Discussion 
Limited access of the population to health facilities and the reluctance of BU patients to seek 
medical care have made house-to-house surveys an attractive tool in studies on the disease 
epidemiology [13–15]. Here, we investigated recent anecdotal accounts of unstable M. ulcerans 
transmission along the Offin river.  
We observed during our survey, scanty passive surveillance data which made our annual BU 
case trend analysis for each community a challenge. BU patients‟ records preserved over time 
could also serve as reliable source of information for retrospective analyses which could add to 
the existing clinical knowledge of the disease. The importance of maintaining good patient 
records was demonstrated in a recent analysis of 1,227 BU case data collected from 2005 to 2011 
in Benin. The study revealed a higher risk of developing osteomyelitis among male patients than 
female patients and a significant association between clinical presentation and development of 
permanent functional sequelae [16]. 
Inhabitants having both healed and active lesions were recorded in the study in order to account 
for historical trends as well as to get an overview of the current BU situation for each 
community. While only laboratory confirmed BU patients with active lesions were included, 
case definition for patients with healed lesions was based on clinical judgment. In view of the 
lack of passive surveillance data on BU for the study communities, findings of this study may 
thus serve as a reference for future longitudinal follow-up of the community.  
In line with the decline in BU incidence in West Africa, Ghana recorded in 2014 nearly 50% less 
cases than in 2009 [2]. Along these lines, one key observation of this study is the overall decline 
in the prevalence of BU along the Offin river, even in known historically endemic communities. 
The high focal BU incidence recorded for Wromanso (K) in 2011 was perhaps due to an increase 
in community sensitization and awareness campaigns about BU conducted within the year. 
Consequently, this may have led to an increase in cases reporting to the health facilities or 
detection of more cases by the health staff through the awareness programs. However, some 
studies have reported similar upsurges in BU incidence in association with climatic and 
environmental changes [17–19].  
In endemic communities of Africa, children have been reported as forming the majority of BU 
cases [20–25]. While children below 15 years of age formed nearly half of all cases detected in 
our study, we observed an underrepresentation of children below 5 years among cases, consistent 
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with the findings of a recent study conducted in Cameroon [14]. Moreover, sero-epidemiological 
studies in Ghana and Cameroon demonstrated that children of this age group were less exposed 
to M. ulcerans [26]. 
Consistent with findings of a previous study conducted along the Densu river in Ghana [13], we 
observed a very low prevalence of BU upstream the river whereas mid and downstream 
communities recorded high prevalence. Similar to the repeated association of BU with man-
made modification of aquatic environments [11,17,18,23,27–29], the intense gold mining 
activities observed in our study area were also localized mid and downstream the river. Recently, 
a detailed study on land cover and its association with BU in the downstream region of the Offin 
demonstrated a significant association between mining and the occurrence of the disease [10]. In 
the same study, the distribution of alluvial gold mining patches in areas of BU foci was made 
evident using high resolution satellite images. The low-lying feature of the mid and downstream 
regions of the river  also supports previously reported association of BU with landscapes of low 
elevation [30,31,28]. 
The monthly household-based surveillance conducted by the community volunteers in the course 
of this study resulted in the detection of seven of the eight laboratory confirmed active BU cases, 
all of whom had early stage lesions. This underscores the important role of community 
volunteers in early case detection and uncomplicated treatment of BU [32–34]. However, ideally, 
only category I lesions should have been detected considering that active surveillance strategies 
were employed to monitor the emergence of new cases after the exhaustive case search. This 
could be explained that some early lesions were missed since the volunteers couldn‟t consistently 
achieve 100% household coverage. Alternatively some patients may have ignored the very early 
clinical BU signs and may have only presented themselves to the volunteers on such visits when 
lesions have progressed to category II. As reviewed [35] and previously reported [36] patients 
with large active lesions may play a role in transmission of M. ulcerans by disseminating the 
bacteria from their active lesions into the environment which may then serve as a source of 
infection to others. This implies that intense continuous early case detection and timely antibiotic 
treatment in an endemic area may result in the interruption of this cycle leading to the gradual 
decline of cases, as observed for example in Ghana and Benin.  
The current active surveillance approach employed by the BU control programs is mainly 
community based. One cost effective way to sustain the monthly household surveillance will be 
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to integrate the BU surveillance with other prevalent skin diseases like yaws, cutaneous 
leishmaniasis and leprosy [37]. As a tool, the mobile phone data collection can serve as a back-
up to address the gaps in data collected at the health facility or district levels. 
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2.8 Figures 
 
Figure 2.1. Study area. Map of Ghana showing major river systems. Our study area comprised 
part of the Offin river basin, shown here with a red rectangle. The  Pra River is indicated by the 
dotted line. 
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Figure 2.2. Land cover and use in selected communities along the Offin river. 
Upstream communities (A) Bedomase and (B) Krakrom, mid-stream community (C) Ntobroso 
and downstream community (D) Pokukrom  
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Figure 2.3. Elevation and distribution of Buruli ulcer burden along the Offin River. 
(A) A map showing communities located within the 5 km buffer along the Offin river. The 10 red colored 
study communities were randomly selected, the three yellow colored communities were added to the 
study based on recommendations by local health staff. (B) Spatial distribution of  Buruli ulcer prevalence 
along the Offin river. (C) Spatial altitudes variation (indicated in feet) along the Offin river. The 
Mampong highland area is indicated by the yellow star.  
Community codes; Bedomase (A), Krakrom (B), Kapro (C), Akomfore (D), Ntobroso (E), Achiase (F), 
Keniago (G), Tontonkrom (H), Dominase (I), Nkotumso (J) Wromanso (K), Mfantseman (L) and 
Pokukrom (M). 
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Figure 2.4. Population age distribution and age adjusted prevalence of BU in the surveyed 
population. (A) Age distribution of the surveyed population (n = 20,390 inhabitants) of the 13 
selected study communities in the Offin river basin. (B) Age distribution of BU cases based on 
the age of the 480 identified cases at onset of the disease adjusted for age (per 1,000 inhabitants) 
using the age structure of the general surveyed population  
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Figure 2.5. Estimated annual case trend for communities located mid-stream of the Offin 
river. Trends were reconstructed using data from active survey (ACS) and passive surveillance 
data (PCS) available at the local and district health facilities. The red star represents unavailable 
passive surveillance data for a particular year. Community codes: D (Akomfore), E (Ntobroso), 
F(Achiase), G (Keniago), H (Tontonkrom). No case was detected in Bedomase (A) and index 
cases were detected in Krakrom (B) and Kapro (C) 
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Figure 2.6. Estimated annual case trend for communities located down-stream of the Offin 
river. Trends were reconstructed using data from active survey (ACS) and passive surveillance 
data (PCS) available at the local and district health facilities. The red star represents unavailable 
passive surveillance data for a particular year. Community codes: I (Dominase), J (Nkotumso), 
K (Wromanso), L (Mfantseman), M (Pokukrom). 
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Figure 2.7. Monthly active surveillance of BU in the Achiase community. Graph shows data 
obtained from Achiase by monthly household visits. Black bars represent percentage of 
households covered by the volunteer, grey bars represent the number of suspected cases and 
white bars represent the number of laboratory confirmed cases.  
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2.9 Tables  
Demographic 
variables 
Community 
A B C D E F G H I J K L M Total 
Population (n) 1,688 111 692 1,016 1,949 1,900 3,350 2,945 2,802 2,518 216 303 900 20,390 
Type of 
settlement 
Peri-
urban 
Hamlet Village Village Village Village Village Village Peri-
urban 
Peri-
urban 
Hamlet Hamlet Village  
Households               
Inhabitants 
per household 
1-25 2-17 2-25 1-20 1-30 1-21 1-32 1-25 1-27 1-30 1-20 1-10 1-19 1-32 
Total number 
of households 
226 16 64 157 251 295 413 399 384 370 41 85 121 2,822 
Residents               
Full time (%) 87.5 84.7 93.8 89.1 84.8 92.2 86.3 93.1 92.1 93.2 74.1 90.8 91.3 90 
Part time (%) 12.5 15.3 6.2 10.9 15.2 7.8 13.7 6.9 7.9 6.8 25.9 9.2 8.7 10 
Total 100 100 100 100 100 100 100 100 100 100 100 100 100  
Sex               
Females, n 
(%) 
876 
(51.9) 
65 
(58.6) 
363 
(52.5) 
499 
(49.1) 
972 
(49.9) 
939 
(49.4) 
1,719 
(51.3) 
1,467 
(49.8) 
1,423 
(50.8) 
1,232 
(48.9) 
106 
(49.1) 
141 
(46.5) 
409 
(45.4) 
10,211 
Age range 0.2-
110 
0.5-72 0.2-
100 
0-120 0.2-
115 
0.1-
120 
0-120 0.1-
114 
0-110 0-100 1-85 0.3-90 0.1-99 0-120 
Mean age in 
years ( S.D) 
24.3 
(20.7) 
22.4 
(17.4) 
24.0 
(19.9) 
23.1 
(18.8) 
24.4 
(18.9) 
25.9 
(20.7) 
22.9 
(19.4) 
22.2 
(16.6) 
22.9 
(17.9) 
23.3 
(17.7) 
27.0 
(20.3) 
23.3 
(18.0) 
24.3 
(18.4) 
23.6 
(18.8) 
Ethnicity (%)               
Akan 88 53.5 96.5 79 94.2 90.4 46.9 71.6 82.6 68.2 53.8 73.6 92.1 75.8 
Ewe 0.3 3.3 0 8.7 0.1 1.2 0.9 6.6 9.6 14.5 30 2.1 6 5.4 
Mole 0.3 0 0.1 0.1 0 0.1 0 0 0.2 0.6 0 0.3 0 0.1 
Ga / Ada 0.2 1.2 0 3 0.4 0.2 0 0.7 1.4 1.6 1 0.5 0.5 0.8 
Guan 0.1 0.1 0 0 0 0 0 0 0.1 0 0 0.3 0 0 
Gruma 1.6 5.4 0 0 0 0.3 1.8 1 0.1 0.5 2 0.4 0 0.7 
Grusi 0 0.1 0.1 0.2 0 0.4 0 0 0.7 0.9 0 2.6 0 0.3 
Mande 0.1 0.1 0 0 0.1 0 0 0 0 0 0.1 0.5 0 0 
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Mamprusi 0 0.2 0 0.1 0.3 0.2 0 0 0 0.1 0.1 0.8 0 0.1 
Kussasi 3.9 13.3 2.4 1.8 0.4 3.9 31.5 5.3 2.7 2.8 4.2 3.7 0 7.7 
Others 5.5 22.8 0.9 7.1 4.5 3.3 18.9 14.8 2.6 10.8 8.8 15.2 1.4 9 
Total 100 100 100 100 100 100 100 100 100 100 100 100 100  
Main 
Occupation 
(%) 
              
Unemployed 
(children and 
elderly) 
12.6 15.3 16.5 17.1 16.7 13.8 20.9 15.1 12.8 13.4 12.1 13.2 13.8 14 
Unemployed 
(Adult) 
6.8 1.8 6.4 4.2 4.4 3.2 6.2 3 14.2 8.6 2.8 4 8.2 8 
Student 42.4 38.8 36.7 32 28.7 33.1 33.8 28.5 22.7 12.8 29.6 32 28.4 28 
Fisherman 0 0 0 0.1 0.2 0 0.1 0 5.2 18.4 0.5 0 0 0 
Farmer 21 38.7 24.4 36.1 28.3 31.3 17.5 18 14 9 36.1 40.9 21 21 
Miner 0.4 0 0 4.7 8.8 9.5 12.2 24.4 14.7 18.9 9.7 5.6 17.1 17 
Skilled 
laborer 
7.7 1.8 3 2 5.2 3.8 3.2 2.9 5.8 4 3.2 1.3 3 3 
Unskilled 
laborer 
8.8 3.6 11.7 2.5 6.3 4.6 5 7 9.4 13.5 4.6 2.3 7.2 7 
Others 0.3 0 1.3 1.3 1.4 0.7 1.1 1.1 1.2 1.4 1.4 0.7 1.3 1 
Total 100 100 100 100 100 100 100 100 100 100 100 100 100  
BU 
Prevalence(%) 
              
Healed cases 0 0.9 0.1 3 1.6 3.8 1.2 3.2 2.5 3.6 2.3 8.9 1.3 2.3 
Active cases 0 0 0 0.1 0.1 0.1 0 0 0 0 0 0 0 0 
 
Table 2.1. Demographic characteristics of the surveyed population. 
Community codes:  Bedomase (A), Krakrom (B), Kapro (C), Akomfore (D), Notbroso (E), Achiase (F), Keniago (G), Tontonkrom 
(H), Dominase (I), Nkotumso (J) Wromanso (K), Mfantseman (L) Pokukrom (M) 
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3.1 Abstract 
A previous survey for clinical cases of Buruli ulcer (BU) in the Mapé Basin of Cameroon 
suggested that, compared to older age groups, very young children may be less exposed to 
Mycobacterium ulcerans. Here we determined serum IgG titres against the 18 kDa small heat 
shock protein (shsp) of M. ulcerans in 875 individuals living in the BU endemic river basins of 
the Mapé in Cameroon and the Densu in Ghana. While none of the sera collected from children 
below the age of four contained significant amounts of 18 kDa shsp specific antibodies, the 
majority of sera had high IgG titres against the Plasmodium falciparum merozoite surface 
protein 1 (MSP-1). These data suggest that exposure to M. ulcerans increases at an age which 
coincides with the children moving further away from their homes and having more intense 
environmental contact, including exposure to water bodies at the periphery of their villages. 
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3.2 Author Summary 
Although M. ulcerans, the causative agent of Buruli ulcer (BU), was identified in 1948, its 
transmission pathways and environmental reservoirs remain poorly understood. The occurrence 
of M. ulcerans infections in endemic countries in West and Central Africa is highly focal and 
associated with stagnant and slow flowing water bodies. BU is often described as a disease 
mainly affecting children <15 years of age. However, taking the population age distribution into 
account, our recent longitudinal survey for BU in the Mapé Dam Region of Cameroon revealed 
that clinical cases of BU among children <5 years are relatively rare. In accordance with these 
findings, data of the present sero-epidemiological study indicate that children <4 years old are 
less exposed to M. ulcerans than older children. Sero-conversion is associated with age, which 
may be due to age-related changes in behavioural factors, such as a wider movement radius of 
older children, including more frequent contact with water bodies at the periphery of their 
villages. 
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3.3 Introduction 
It has been established that the chronic necrotizing skin disease BU is caused by the emerging 
pathogen Mycobacterium ulcerans, however the mode(s) of transmission and environmental 
reservoirs are still unknown. Comparative genetic studies have revealed that M. ulcerans has 
diverged from the fish pathogen M. marinum. Through the acquisition of a plasmid, M. ulcerans 
has gained the ability to produce a cytotoxic and immunosuppressive macrolide toxin, referred to 
as mycolactone [1,2]. In addition to M. ulcerans strains isolated from human lesions, which 
belong either to the classical or to the ancestral lineage [3], other mycolactone-producing 
mycobacteria (MPM) have been identified as fish and frog pathogens and given diverse species 
names [4-7]. However, recent comparative genomic analyses have shown that all MPM are 
genetically closely related and can be divided into three principal ecovars of M. ulcerans [8]. 
Extensive pseudogene formation and genome downsizing of the human M. ulcerans pathogen 
are indicative for an adaptation to a more stable ecological niche. In African endemic settings 
both the physical environment and organisms such as amoeba, insects, fish and frogs have been 
proposed as possible environmental reservoirs of the pathogen [9]. Accordingly, direct 
inoculation of bacteria into the skin from an environmental reservoir, but also bites from insects, 
such as mosquitos or water bugs have been suggested as route of infection. While possums have 
been identified as an animal reservoir in BU endemic areas of Southern Australia [10], no 
mammalian reservoir has so far been detected in Africa. The distribution pattern of lesions is not 
indicative for a particular route of infection [11] and a genetic fingerprinting study of M. 
ulcerans isolates has revealed a highly focal transmission pattern, which excludes certain modes 
of transmission [12]. 
While it has long been generalized that in African BU endemic areas children below the age of 
15 are most affected by the disease [13], population age-stratified data from our previous survey 
for BU in the Mapé Basin of Cameroon showed that children less than 5 years old were 
underrepresented among cases [11]. One explanation for this observation may be a lower degree 
of exposure of very young children to M. ulcerans. Sero-epidemiological studies in Ghana have 
shown that screening blood sera of local populations for the presence of IgG specific for the 18 
kDa shsp of M. ulcerans represents a tool to monitor exposure of populations to M. ulcerans 
[14]. However, in these investigations study participants were older than 5 years of age. Since a 
proportion of study participants of all age groups tested positive, it is still not known at which 
Chapter 3 – Sero-epidemiology of M. ulcerans 
 
59 
 
age immune responses against M. ulcerans start to emerge and hence where and at which age 
exposure to the pathogen begins.   
In the present sero-epidemiological study the potential association between age and exposure to 
M. ulcerans was investigated by determining anti-18 kDa shsp IgG titres in 875 individuals from 
BU endemic sites in the Densu River Basin of Ghana and the Mapé Basin of Cameroon. In these 
cross-sectional surveys we included more than 100 children less than 5 years old allowing us to 
estimate the age of sero-conversion, which may provide another cornerstone in the search for the 
mode of M. ulcerans transmission. 
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3.4 Materials and Methods  
Ethics statement 
Ethical clearance for the collection and testing of human blood samples from Ghana and 
Cameroon was obtained from the institutional review board of the Noguchi Memorial Institute 
for Medical Research (Federal-wide Assurance number FWA00001824) and the Cameroon 
National Ethics Committee (N°172/CNE/SE/201) as well as the Ethics Committee of Basel 
(EKBB, reference no. 53/11). Written informed consent was obtained from all individuals 
involved in the study. Parents or guardians provided written consent on behalf of children. 
 
Study design  
We investigated the association between age and exposure to M. ulcerans by determining serum 
antibody titres against the 18 kDa shsp in individuals living in two different BU endemic areas.   
In Cameroon, serum samples were collected from inhabitants of the village of Mbandji 2. This 
village is located in the Bankim Rural Health Area of the Bankim Health District, where we 
conducted a cross-sectional house-by-house survey for BU in early 2010, including the 
collection of data on the population age structure. These data and the subsequent identification of 
BU cases until June 2012 were published in our previous study [11]. In the present study we 
provide updated information based on a continued monitoring of new BU cases in this area until 
May 2013. The age-specific incidence rates were calculated using the ages of the BU cases 
identified between March 2010 and May 2013 and the population age distribution as collected in 
the house-by-house survey in the Bankim Health District.  
Sera were collected in January 2011 from all inhabitants of Mbandji 2, who agreed to participate 
(395 individuals with a nearly equal gender distribution). Re-sampling of 80 blood donors from 
Mbandji 2 was carried out one year after the first blood collection to analyze stability of anti-18 
kDa shsp serum IgG levels over time. 
The second study site comprised villages within the Obom sub-district of the Ga-South district in 
Ghana. This sub-district is one of the major BU endemic communities along the Densu River 
Basin. The villages from which the sera were collected, have active transmission on-going as 
they have continuously reported cases for the past five years. Study participants included 96 
laboratory confirmed BU patients (57 females and 39 males) as well as 4 age-, sex-, and home 
village-matched controls for each patient (384 control individuals).  
Chapter 3 – Sero-epidemiology of M. ulcerans 
 
61 
 
Demographic data as well as history of known previous mycobacterial infections were recorded 
for all participants at both sites. While the majority of individuals had no history of 
mycobacterial infections, eight study participants from Mbandji 2 reported to having had 
tuberculosis (2), leprosy (1) or BU (5). All control participants recruited in Ghana had no history 
of mycobacterial infection. The age distribution of study participants from Cameroon and Ghana 
is shown in Figure 3.1A and 3.1B, respectively. 
Blood sera from the 875 individuals were tested for the presence of anti-18 kDa shsp antibodies 
in an ELISA format. In addition, 96 sera from children living in Mbandji 2 were tested by 
Western Blot analysis for the presence of antibodies against this protein, as well as against a 
Plasmodium falciparum MSP-1 protein domain in order to assess the exposure and immune 
responses of child study participants to this mosquito transmitted parasite. 
 
ELISA 
96-well Nunc-Immuno Maxisorp plates (Thermo Scientific) were coated with 0.25 g 
recombinant M. ulcerans 18 kDa shsp per well in 100 l phosphate-buffered saline (PBS) and 
incubated over night at 4°C. Plates were washed four times with washing buffer (dH2O, 2.5 % 
Tween 20) before being incubated with blocking buffer 1 (5 % skim milk in PBS) for 2 hours at 
room temperature (RT). After washing as described above, 50 l of 1:100 diluted human blood 
sera in blocking buffer 2 (1 % skim milk in PBS) was added to each well and incubated for 2 
hours at RT. Following a further washing step, 50 l of 1:8000 diluted goat anti-human IgG (γ-
chain specific) antibodies coupled to horseradish peroxidase (HRP, SouthernBiotech) in blocking 
buffer 2 was added to each well and incubated for 1.5 hours at RT. Plates were washed and 50 µl 
TMB Microwell Peroxidase Substrate (KPL) was added per well. The reaction was stopped after 
5 minutes using 0.16 M sulfuric acid. The absorbance was measured at 450 nm in a Tecan 
Sunrise microplate reader.  
 
Western Blot analysis 
15 g of recombinant M. ulcerans 18 kDa shsp or 5 g of a Plasmodium falciparum MSP-1 
protein domain (amino acids 34-469 of strain K1) were separated on NuPAGE Novex 4-12 % 
Bis-Tris ZOOM Gels with 1.0 mm IPG well (Invitrogen) using NuPAGE MES SDS Running 
Buffer (Invitrogen) under reducing conditions. After electrophoresis the proteins were 
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transferred onto nitrocellulose membranes using an iBlot Gel Transfer Device (Invitrogen). 
Membranes were blocked with blocking buffer 3 (5 % skim milk in PBS containing 0.1 % 
Tween 20) and cut into thin strips. Membrane strips were then incubated with human blood sera 
at a 1:1000 dilution in blocking buffer 3 for 2 hours at RT. Strips were repeatedly washed with 
0.3 M PBS containing 1 % Tween 20 and after that incubated with 1:20‟000 diluted goat anti-
human IgG (γ-chain specific) antibodies coupled to HRP (SouthernBiotech) for 1 hour at RT. 
After a second washing step, bands were visualized by chemiluminescence using ECL Western 
Blotting substrate (Pierce). 
 
Data analysis 
ELISA results were analyzed using GraphPad Prism version 6.0 (GraphPad Software, San Diego 
California USA) and R version 3.0.1 [15]. 
The distribution of antibody titres and the differences between two successive antibody titres are 
presented as box plots.  These comprise a line for the median, edges for the 25th and 75th 
percentiles and traditional Tukey whiskers showing 1.5 times the interquartile distance. Dots on 
the graph represent individual points that lie outside that range.  
We compared changes in OD between age categories in the Cameroon dataset using the Kruskal-
Wallis test. Levene‟s test for homogeneity of variances was used to compare the degree of 
variation by age category. We compared the OD values for the Ghana matched cases and 
controls using conditional logistic regression.  
The overall bias and variation between the first and second Ghanaian serum samples was 
estimated using the Bland-Altman method [16]. 
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3.5 Results 
Age distribution of BU incidence and M. ulcerans 18 kDa shsp-specific serum IgG 
responses among individuals living in the Mapé Basin of Cameroon 
The age-specific BU incidence rates for the population in the Mapè Basin were calculated using 
76 BU cases identified between March 2010 and May 2013.  Based on these cases, a low 
incidence rate of BU was detected for children less than 4 years of age (Figure 3.2A).  
The age-distribution of IgG titres against the M. ulcerans 18 kDa shsp for a cross-sectional 
survey of 395 individuals from the village Mbandji 2 is shown in Figure 3.2B. While high 
antibody titres were detected in individuals of all age groups over 4 years, none of the children 
younger than four years showed an ELISA IgG titre above the background, which was 
determined by Western Blot analysis as OD < 0.35.  Analysis of the 96 sera sampled from 
children less than 7 years old by Western Blot analysis showed no specific bands representing 
IgG antibodies against the 18 kDa shsp for sera from children <4 years of age (Figure 3.3). In 
contrast, Western blot positive sera were found in all tested age groups >4 years old. Since very 
weak IgG titres were recorded for some of the sera from four year olds, sero-conversion may 
start in some children around this age.   
 
Serum IgG responses against a domain of Plasmodium falciparum merozoite surface 
protein 1 among children living in the Mapé Basin of Cameroon 
IgG titres against a recombinant fragment of MSP-1 were determined by Western Blot analysis.  
In contrast to the lack of antibody responses against the 18 kDa shsp in children <4 years old, 
serum IgG responses against the P. falciparum malaria parasite MSP-1 domain were detected in 
all age groups tested. Strong staining of the MSP-1 band was observed for the majority of sera 
collected from children between one and seven years of age as well as for one of the infants 
(Figure 3.4).  
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Stability of anti-18 kDa shsp IgG titres  
One year after the first serum collection in Mbandji 2, 80 of the 395 study participants were re-
sampled. While only minimal changes in antibody titres against the 18 kDa shsp were recorded 
overall, more individuals had a decreased than an increased serum IgG level after one year 
(Figure 3.5A).  
Increases in OD tended to be small and confined to the older children and young adults (Figure 
3.5B). The most distinct changes, characterized by a marked decrease of antibody titres between 
the two surveys, occurred in young adults.  
There was a significant association between age group and the absolute change in OD (Kruskal-
Wallis test p=0.01) and borderline evidence of an association between the variation in changes in 
OD and age group (Levene‟s test for homogeneity of variances, p=0.08).    
 
M. ulcerans 18 kDa shsp specific serum IgG responses in BU patients and control 
individuals living in the BU endemic Densu River Valley of Ghana 
M. ulcerans 18 kDa shsp specific IgG titres were also determined in sera from 96 BU patients 
and 384 healthy matched control individuals living in a second BU endemic site in West Africa, 
the Densu River Valley in Ghana. Each serum sample was tested twice, once in each of two 
independent experiments (Figure S3.1). Negligible overall bias between experiments was 
observed with the mean difference (OD1-OD2) of 0.024. There was also a reasonably small 
variation in the individual differences with the 95 % limits of agreement from -0.0796 to 0.1278. 
There was no evidence of a difference in the ELISA OD values between the cases and controls 
(p=0.99) (Figure 3.6A).  
While sero-responders were identified in all age groups of individuals more than 6 years old, 
none of the sera from children younger than 5 years exhibited a distinct anti-18 kDa shsp IgG 
titre (Figure 3.6B). Results of representative subsets of sera which tested negative, moderately 
positive or highly positive by ELISA were reconfirmed by Western blot analysis, showing good 
agreement between ELISA OD values and Western Blot band intensities (Figure S3.2). 
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3.6 Discussion 
A high degree of antigenic cross-reactivity among mycobacterial species complicates 
investigations on M. ulcerans-specific humoral immune responses. However, the 
immunodominant 18 kDa shsp [17], which is overexpressed in M. ulcerans [18], represents a 
suitable serological marker for exposure to M. ulcerans [14]. Diverse outcomes of infection with 
other mycobacteria, such as M. tuberculosis and M. leprae have been associated with both host 
and pathogen factors. While only one study has investigated a possible association between BU 
and host genetics [19], various behavioural factors that may lead to increased risk to develop the 
disease have been reported, with poor wound care, failure to wear protective clothing, and living 
or working near water bodies being the most common risk factors identified [20]. While the 
generalization persists that children <15 years old are most affected by the disease [13], our 
recent survey for BU in the Mapé Basin [11] and continued monitoring of new BU cases in this 
region have revealed that the risk of BU is as high in individuals above the age of 50 as in young 
teenagers and that very young children below the age of four are underrepresented among cases 
when adjusting for the population age distribution. Data of our previous sero-epidemiological 
investigations revealed that the proportion of individuals from a BU endemic area showing 
serum IgG titres against the 18 kDa shsp of M. ulcerans is comparable for all age groups >5 
years [14]. Results of the present study, including for the first time a substantial number of serum 
samples from children <5 years of age, showed that children of this age group have not yet sero-
converted. Hence, young children appear to be considerably less exposed to M. ulcerans. This 
reduced exposure may be explained by the smaller movement radius away from the house of 
these very young children. Although, these small children do leave the house, they usually do so 
being carried by a caregiver and are therefore not in direct contact with the environment, at more 
distant places from their homes. No significant difference could be observed when comparing 
anti-M. ulcerans 18 kDa shsp antibody titres between BU patients and controls. This may be 
related to the immune-suppressive effect of mycolactone and concurs with the lack of a 
serological response in experimentally infected mice (unpublished data). 
The results of a case-control study carried out in a BU endemic region of south-eastern Australia 
indicated reduced odds of having BU for individuals who frequently used insect repellent and 
increased odds for those who were bitten by mosquitoes [21]. In African BU endemic settings, 
the highly focal transmission of M. ulcerans haplotypes [12,22,23], as well as the distribution 
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pattern of BU lesions on the body [11], speak against an exclusive role of mosquito vectors in 
transmission. Here we observed in children <5 years frequent sero-conversion for the MSP-1 
antigen of the mosquito-transmitted malaria parasites in the absence of an IgG response against 
the M. ulcerans 18 kDa shsp. The age distribution of BU cases and the relatively abrupt changes 
in this risk of contracting BU with age do not speak for transmission of BU by mosquito species 
commonly found within the small movement radius of very young children.  
Within the framework of our analyses, blood was collected for a second time from a limited 
number of participants one year after the first sample. Results of this pilot study showed that 
anti-18 kDa shsp IgG titres were relatively stable in older adults. Future studies of the age-related 
changes in behaviour of three to six year old children, monitoring of their movement radius and 
water contact patterns in combination with larger longitudinal serological and environmental 
studies may have the potential to shed further light onto the mode of transmission and relevant 
environmental reservoirs of M. ulcerans. 
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3.7 Figures 
 
Figure 3.1. Age distribution of study participants. A In Cameroon, serum samples were 
collected from 395 healthy individuals from the BU endemic village of Mbandji 2. B In the 
Obom sub-district of the Ga-South district in Ghana, blood sera were collected from 96 BU 
patients (black) and 384 control individuals (grey) of the different age groups shown. 
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Figure 3.2. Age distribution of BU incidence and anti-18 kDa shsp IgG serum titres among 
healthy inhabitants of Mbandji 2. A Incidence of reported BU by age in the Bankim Health 
District (March 2010 – May 2013). B Boxplot of OD values of 1:100 diluted serum samples 
from inhabitants of Mbandji 2 tested in an anti-M. ulcerans 18 kDa shsp IgG specific ELISA by 
age group. No IgG titres above the background level were observed for children below the age of 
four. The background response (OD = 0.35) is indicated as a dotted line. 
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Figure 3.3. Western blot analysis of anti-18 kDa shsp IgG responses in children. Sera collected from children living in Mbandji 2 
were tested for the presence of anti-M. ulcerans 18 kDa shsp IgG by Western Blot analysis. No specific bands were detected for very 
young children below the age of four. An ELISA positive control serum (OD = 0.963) was included between each of the age groups 
tested (+; arrow at band corresponding to size of the 18 kDa shsp). 
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Figure 3.4. Western blot analysis of anti-P. falciparum MSP-1 IgG responses in children. Sera from children living in Mbandji 2 
were tested for IgG responses against a domain of the P. falciparum MSP-1 protein by Western Blot analysis. Specific bands were 
detected in the majority of individuals of all tested age groups above 1 year. The band corresponding to the specific signal of the MSP-
1 protein domain is indicated with an arrow. 
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Figure 3.5. Changes in anti-M. ulcerans 18 kDa shsp IgG titres in sequentially collected 
serum samples. An IgG titres against the M. ulcerans 18 kDa shsp were determined in serial 
serum samples collected from 80 individuals. The majority of changes were small and most 
individuals showed a slightly decreased titre after one year. B Boxplot of differences in OD 
values between the two samples are shown by age group. Changes in antibody titres were most 
pronounced in young adults. 
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Figure 3.6. Anti-M. ulcerans 18 kDa shsp IgG titres in sera from Ghanaian BU patients and 
control individuals. A Box plots showing OD values of 1:100 diluted sera from Ghanaian BU 
patients (n = 96) and control individuals (n = 384) tested in an anti-M. ulcerans 18 kDa shsp IgG 
specific ELISA. B Boxplot showing the distribution of OD values for BU patients and control 
individuals for different age groups. No IgG titres above the background level were observed for 
children below the age of 5 years. The background response (OD = 0.35) is indicated as a dotted 
line. C Sera from eight 2-year-old children were tested by Western Blot analysis to reconfirm the 
absence of anti-M. ulcerans 18 kDa shsp IgG. An ELISA positive control serum (OD = 0.76) 
was included (+) flanking the tested sera. 
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3.7.1 Supplementary Figures 
 
Figure S3.1. Duplicate ELISA testing of sera. All serum samples collected from individuals 
living in the BU endemic Densu River Basin of Ghana were tested twice (screen 1 and screen 2). 
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Figure S3.2. Reconfirmatory Western blot of randomly chosen Ghanaian sera. A subset of 
sera from Ghana which tested moderately positive (OD = 0.58–0.64), negative (OD = 0.1) and 
highly positive (OD = 1.0–1.2) by ELISA were tested by Western Blot analysis. Specific bands 
were detected for ELISA positive sera, while no signal was obtained for ELISA negative sera. 
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4.1 Abstract 
The debilitating skin disease Buruli ulcer (BU) is caused by infection with Mycobacterium 
ulcerans. While various hypotheses on potential reservoirs and vectors of M. ulcerans exist, the 
mode of transmission has remained unclear. Epidemiological studies have indicated that children 
below the age of four are less exposed to the pathogen and at lower risk of developing BU than 
older children. In the present study we compared the age at which children begin to develop 
antibody responses against M. ulcerans with the age pattern of responses to other pathogens 
transmitted by various mechanisms. A total of 1,352 sera from individuals living in the BU 
endemic Offin river valley of Ghana were included in the study. While first serological responses 
to the mosquito transmitted malaria parasite Plasmodium falciparum and to soil transmitted 
Strongyloides helminths emerged around the age of one and two years, sero-conversion for M. 
ulcerans and for the water transmitted trematode Schistosoma mansoni occurred at around four 
and five years, respectively. Our data suggest that exposure to M. ulcerans intensifies strongly at 
the age when children start to have more intense contact with the environment, outside the small 
movement range of young children. Further results from our serological investigations in the 
Offin river valley also indicate ongoing transmission of Treponema pallidum, the causative agent 
of yaws. 
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4.2 Author Summary 
Buruli ulcer is a debilitating skin disease caused by Mycobacterium ulcerans. Although the 
understanding of this enigmatic pathogen has improved after decades of research, the mode of 
transmission is yet to be fully elucidated. Recent epidemiological studies have shown an 
underrepresentation of Buruli ulcer cases in children below the age of four as compared to older 
children. In order to investigate the different exposure of children to M. ulcerans and to several 
other pathogens with diverse modes of transmission, we conducted a sero-epidemiological study 
of 1,352 residents within a five kilometer radius along the Offin River of Ghana. While our 
results show early exposure of children to the mosquito transmitted malaria parasite Plasmodium 
falciparum as well as to soil transmitted helminths of the genus Strongyloides, a later onset of 
immune response was observed at an age of around four and five years for M. ulcerans and the 
trematode Schistosoma mansoni, that is transmitted by contact with infested water. Similarities in 
age-dependent exposure of these two pathogens suggest that transmission may take place outside 
of the very young children‟s movement range when they come into contact with the environment 
at the periphery of their villages. 
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4.3 Introduction 
Buruli ulcer (BU) is a neglected tropical skin disease presenting with a wide range of cutaneous 
manifestations, from non-ulcerated nodules, plaques or oedema to characteristic necrotizing 
ulcers [1]. While BU cases have been reported in more than 30 countries worldwide, most 
patients are from infection foci located in remote and rural tropical regions of West and Central 
Africa. BU is caused by infection with Mycobacterium ulcerans, a pathogen that has emerged 
from M. marinum by acquiring a plasmid conferring the capacity of producing the unique 
macrolide toxin mycolactone, accounting for much of the pathology of BU [2,3]. Until today, the 
mode of transmission of M. ulcerans has remained inconclusive, although proximity to aquatic 
habitats has long been identified as the major risk factor for contracting the disease [4]. Infection 
is thought to take place through either physical contact with undefined environmental reservoirs 
via skin abrasions or insect vectors [5–7].  
It has long been recognized that in African BU endemic settings the majority of BU patients are 
children below 15 years of age [8]. However, a clear underrepresentation of children below the 
age of four becomes evident when the population age distribution is taken into account [9,10]. In 
line with this observation, our previous sero-epidemiological studies in Ghana and Cameroon 
have indicated that children below five years of age rarely develop antibody responses against 
the 18 kDa small heat shock protein (shsp) of M. ulcerans and thus seem to be considerably less 
exposed to the pathogen than older children [11]. While investigations of humoral immune 
responses against mycobacteria are complicated by a high degree of antigenic cross-reactivity 
between species, the immunodominant 18 kDa shsp overexpressed by M. ulcerans [12] 
represents a suitable marker for exposure to this pathogen [13]. It has no homologues in other 
prevalent pathogenic mycobacteria such as M. bovis and M. tuberculosis and additionally, sera 
from inhabitants of BU non-endemic regions generally showed no reactivity with this protein 
[13]. While populations living in BU non-endemic communities in proximity to the BU endemic 
regions seem to be similarly exposed to the 18 kDa shsp of M. ulcerans [14,15], we have 
observed for the three Ghanaian BU endemic river valleys Densu [15], Offin (this report) and 
Volta [15] an association between BU prevalence and the percentage of healthy individuals that 
have sero-converted.  
Here we present a sero-epidemiological study carried out in the BU endemic Offin river valley of 
Ghana including 1,352 participants from 13 communities. The main objective was to compare 
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the age-pattern of first humoral immune responses to the 18 kDa shsp of M. ulcerans with those 
to pathogens with various modes of transmission in order to contribute to our understanding of 
the transmission of M. ulcerans. 
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4.4 Methods 
Ethics statement 
Ethical clearance for the study was obtained from the institutional review board of the Noguchi 
Memorial Institute for Medical Research (Federal-wide Assurance number FWA00001824). 
Written informed consent was received from all individuals involved in the study. Parents or 
guardians provided written consent on behalf of their children. 
 
Study area 
The Offin River is one of the major water bodies associated with BU in Ghana. It runs through 
the Ashanti and Central Regions, covering 11 health districts. In a nationwide active BU case 
search conducted in 1999, the Offin river valley was shown to be highly endemic for BU [16].  
A total of 1,560 inhabitants of ten randomly selected communities and an additional three 
communities known to be BU endemic and located within a five kilometer radius along the Offin 
River (120 per community) (Fig. 4.1) were randomly selected for sampling. Two milliliters of 
whole blood were drawn from 1,352 of 1,560 (87%) selected inhabitants in July 2013. In order to 
reduce dropout rates due to repetitive bleeding of participants, we randomly assigned each of the 
sampled individuals to one of three groups (A, B, and C) with each consisting of 450, 451, and 
451 individuals to be followed up after 6 (January 2014), 12 (July 2014) or 18 (January 2015) 
months, respectively. Blood separation was achieved by centrifugation of the whole blood at 
2‟000 x g for 10 minutes. Serum was subsequently stored at -80˚C pending serological analysis. 
First serological analyses were performed between January and July 2014 allowing for a more 
thorough follow up of individual cases, such as sero-converters or sero-reverters. 
 
ELISA to detect anti-M. ulcerans 18 kDa shsp antibodies in serum samples 
ELISA was performed as described previously [11]. Briefly, 96-well Nunc-Immuno Maxisorp 
plates (Thermo Scientific) were coated with 0.25 µg recombinant M. ulcerans 18 kDa shsp per 
well, washed with washing buffer (dH2O, 0.01% Tween 20) and incubated with blocking buffer 
(5% non-fat dry milk in PBS). Subsequently, plates were incubated with human blood serum 
samples (1:100 diluted). After washing, horseradish peroxidase conjugated goat anti-human IgG 
(γ-chain specific, SouthernBiotech) was added. Plates were washed and developed with TMB 
Microwell Peroxidase Substrate (KPL). The reaction was stopped using 0.16 M sulfuric acid. 
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The absorbance was measured at 450 nm in a Tecan Sunrise microplate reader. All samples were 
tested in duplicates and mean values were calculated.  
The cut-off value for positivity (OD450 = 0.25) was determined by testing serum samples with a 
range of ODs in ELISA by Western Blot analysis (Fig. S4.1). Sero-conversion/reversion was 
defined as a change in OD (ΔOD) between baseline and follow up samples of at least ±0.3. 
 
Western Blot analysis to detect anti-M. ulcerans 18 kDa shsp and anti-P. falciparum  
AMA-1 antibodies 
Western Blot analysis was performed as described [11]. Shortly, 15 µg of recombinant M. 
ulcerans 18 kDa shsp or P. falciparum AMA-1 were separated on NuPAGE Novex 4–12% Bis-
Tris ZOOM Gels with 1.0 mm IPG well (Invitrogen) under reducing conditions. After 
electrophoresis, proteins were transferred onto nitrocellulose membranes using an iBlot Gel 
Transfer Device (Invitrogen). Membranes were blocked with 5% non-fat dry milk in PBS 
containing 0.1% Tween 20 and cut into strips. Strips were then incubated with human blood sera 
(1:1000 dilution), washed with 0.3 M PBS containing 1% Tween 20 and thereafter incubated 
with horseradish peroxidase conjugated goat anti-human IgG (γ-chain specific, Southern 
Biotech). After a second washing step, bands were visualized by chemiluminescence using ECL 
Western Blotting substrate (Pierce). 
 
Simultaneous detection of antibodies to treponemal and non-treponemal antigens 
The contagious diseases syphilis and yaws are caused by closely related Treponema pallidum 
spp. Serological diagnosis requires detection of distinct antibodies against both a treponemal 
antigen and a non-treponemal antigen. Non-treponemal tests become reactive during the initial 
stage of infection and generally revert to negative after treatment. However, treponemal antigen-
based confirmation is needed, since detectable antibodies can also be due to other inflammatory 
conditions. Treponemal serological tests on the other hand may remain reactive for life and thus 
require a positive non-treponemal test result to confirm active infection [17].  Here we used the 
Dual Path Platform (DPP) assay manufactured by Chembio Diagnostic Systems for the 
simultaneous detection of antibodies to treponemal and non-treponemal antigens. This 
serological test, which was developed for the point-of-care diagnosis of syphilis [18], was 
Chapter 4 – Sero-epidemiology of Buruli ulcer  
 
84 
 
recently also applied to and evaluated for the screening and detection of patients with yaws [19]. 
We tested 5 µl of the serum samples in strict accordance with the manufacturer‟s instructions.  
 
ELISA to detect antibodies to Schistosoma and Strongyloides antigens 
Preparation of S. mansoni antigens. Soluble egg antigen (SEA) and adult worm antigen extract 
(AWE) were prepared as described previously [20].  Briefly, frozen S. mansoni eggs were 
homogenized in PBS (pH 7.2) on ice and subsequently extracted for 3 hours at 4°C. The extract 
was centrifuged at 100‟000 x g for 2 hours at 4°C and the supernatant was stored in aliquots at -
80°C until use. Adult S. mansoni worms were homogenized in PBS (pH 7.2) containing 2 mM 
PMSF. The extract was centrifuged at 80‟000 x g for 3 hours at 4°C and the pellet was re-
suspended. After overnight incubation at 4°C the suspension was centrifuged again at 80‟000 x g 
for 3 hours at 4°C. The supernatant was concentrated and centrifuged at 15‟300 x g for five 
minutes at 4°C before being stored in aliquots at -80°C until use.  
Both S. mansoni antigens show cross-reactivity with antibodies elicited by other Schistosoma 
ssp. (S. haematobium, S. mekongi or S. japonicum). 
Preparation of S. ratti antigen. Mass production of antigens from S. stercoralis filariform 
larvae suffers the drawbacks of cost, being labor intensive and constituting a risk of infecting 
laboratory technicians handling the larvae. Heterologous antigen of filariform larvae of the rat 
parasite S. ratti provides comparable sensitivity and specificity, thereby making it a suitable 
alternative antigen for sero-diagnosis of human strongyloidiasis [21–23]. For this study, third-
stage larvae (iL3) of S. ratti were collected as described previously [24] and frozen at -80°C. For 
the preparation of raw antigen, larvae were homogenized in PBS (pH 7.2) on ice. Proteins were 
extracted for 24 hours at 4°C on a stirrer and the suspension was centrifuged at 100‟000 x g for 1 
hour at 4°C. The supernatant was stored in aliquots at -80°C.  
Detection of anti-Schistosoma and anti-Strongyloides antibodies by ELISA. Immulon 2HB 
plates (Thermo Labsystems) were coated with S. mansoni or S. ratti antigens in 0.05 M sodium 
carbonate buffer (pH 9.6) for 48 hours at 4°C. After washing with tap water containing 0.05% 
Tween 20, diluted sera (1:160 in PBS, pH 7.2, 0.05% Tween 20) were added to the plates and 
incubated for 15 minutes at 37°C. After additional washing steps, horseradish peroxidase 
conjugated goat anti-human IgG (KPL) was added. Plates were incubated for 15 minutes at 
37°C, subsequently washed and o-Phenylendiamine dihydrochloride (OPD, Sigma) diluted in 0.6 
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M sodium phosphate buffer, pH 5.0 supplemented with 0.03% H2O2 was added. The reaction 
was stopped with 8 M H2SO4 and the absorption was read with a Multiscan FC reader (Thermo 
Scientific) at 492 nm. The presence of anti- Schistosoma antibodies was reconfirmed for the 
serum of a young child by immune fluorescence assay (IFA) carried out as described [20]. Serum 
samples positive in the Strongyloides ELISA were confirmed by re-testing in duplicates. 
Cut-off values (Table 4.1) were determined previously by receiver operating characteristic 
(ROC) analysis of results obtained for 50 sera of healthy Swiss blood donors, 20 sera each of 
patients infected with S. mansoni or S. stercoralis, and 120 sera of individuals with other 
parasitic infections (Fig. S4.2). The sensitivity for the S. mansoni ELISA was 98% and 80% for 
AWE and SEA, respectively, while the specificity was 96% and 92% (Table S4.1). SEA can 
exhibit cross-reactivity with Trichinella and to a lesser extent with Filaria. The sensitivity of the 
S. ratti ELISA was 95%, while the specificity was 84% due to potential cross-reactivity with 
Filaria and Echinococcus ssp (Table S4.1). 
 
Data analysis 
ELISA results were analyzed using GraphPad Prism version 6.0 (GraphPad Software, San Diego 
California USA). The distribution of antibody titers is presented as box plots. These comprise a 
line for the median, edges for the 25th and 75th percentiles and traditional Tukey whiskers 
showing 1.5 times the interquartile distance. Dots on the graph represent individual points that lie 
outside that range. The overall difference and variation between samples tested in duplicates was 
estimated using the Bland-Altman method [25].  
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4.5 Results 
Age distribution of M. ulcerans 18 kDa shsp specific serum IgG responses  
In order to assess exposure of the population living in a five kilometer radius along the Offin 
River to M. ulcerans, serum samples taken from 1,352 study participants of 13 communities 
across different age groups (Table 4.2) were tested in duplicates for the presence of anti- M. 
ulcerans 18 kDa shsp IgG by ELISA. Between the two duplicate test results, a negligible overall 
bias with a mean difference (OD1-OD2) of 0.004 was estimated. The variation in individual 
differences was very small, with 95% limits of agreement from −0.095 to 0.103. At baseline, 
18% of the serum samples contained IgG titers against the M. ulcerans protein. In all, 3% 
(46/1,352) of the participants were BU cases with healed or active lesions and 13% (179/1,352) 
were household contacts of BU patients. Amongst the BU cases, 24% (11/46) had antibodies 
against the M. ulcerans 18 kDa shsp, while 15% (26/179) of the household contacts contained 
anti- M. ulcerans 18 kDa shsp titers in their sera. 
The age distribution of the mean of duplicate anti- M. ulcerans 18 kDa shsp IgG titers for the 
study participants is shown in Fig. 4.2A and Table 4.2. While in all age groups above nine years 
individuals with high IgG titers were detected, only three sera from children below the age of 
five years contained 18 kDa shsp specific antibodies and also most of the sera from children 
between five and seven years tested negative. The only child below four years of age with 
positive test result was a three year old resident of Mfantseman, a BU endemic community. We 
carefully followed up this particularly interesting individual case at two occasions.  Before May 
2013, he lived for his entire life in a BU non-endemic community (Wanpiem) not included in 
this study, but was transferred thereafter to the BU endemic community Mfantseman for 
schooling and was enrolled there in this study. Shortly after sampling his blood in July 2013, he 
was relocated to Wanpiem by his guardian. Scheduled for sampling after 12 months (July 2014), 
we followed him up at Wanpiem and observed that he had sero-reverted. His serum still tested 
negative for anti- M. ulcerans 18 kDa shsp IgG after 18 months of follow up (January 2015). 
Thus, his total length of stay in the BU endemic Mfantseman community was three months 
(May-July 2013); coinciding with the only sampling point at which we observed a high anti- M. 
ulcerans 18 kDa shsp IgG titer in his serum. Western blot results for the three time points 
reconfirmed the ELISA data (Fig. 4.2B). Testing of sera from all other study participants 
younger than five years by Western Blot analysis revealed no specific bands (representing IgG 
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titers) against the 18 kDa shsp for sera from children below four years of age (Fig. S4.3), while 
positive sera were detected in all age groups ≥4 years (Fig S4.3 and S4.4), indicating that sero-
conversion may start in some children around the age of four years. 
 
Stability of anti- M. ulcerans 18 kDa shsp IgG titres 
Follow up samples were taken from 319 of 450 (71%), 329 of 451 (73%), and 356 of 451 (79%) 
participants assigned to groups A, B and C after 6, 12, or 18 months, respectively (Fig 4.3A). 
Testing of the serum samples for the presence of anti- M. ulcerans 18 kDa shsp IgG revealed that 
based on the defined value for the difference between paired samplings (ΔOD = 0.3), antibody 
titers remained stable for 98%, 97%, and 92% of the study participants, respectively. After 6, 12, 
and 18 months 1%, 0.3%, and 6% of the sero-positive individuals had sero-reverted, while 1%, 
3% and 1.4% of the sero-negative participants had sero-converted (Fig 4.3B-D).  
 
Age distribution of IgG titres against antigens of other pathogens with known mechanism 
of transmission 
Plasmodium falciparum. Serum samples collected from children below the age of four years 
were tested for the presence of IgG titers against the AMA-1 protein of the mosquito transmitted 
malaria parasite P. falciparum. In contrast to the late onset of the serological response in children 
for the M. ulcerans 18 kDa shsp, Western Blot analysis for AMA-1 showed that a number of sera 
from one (1/3) and two (7/15) year old infants and almost all sera from three year old children 
(26/37) contained antibodies against this microneme protein of sporozoites and merozoites [26] 
(Fig 4.4, Table 4.2).  
Treponema pallidum. Serum samples from all children below the age of 11 years (n = 402) and 
representatives of older age groups (n = 217) were analyzed for the presence of antibodies 
against non-treponemal and treponemal antigens using the DPP Screen and Confirm assay 
(Chembio Diagnostic Systems). Antibodies against both treponemal and non-treponemal 
antigens were detected in sera from only a limited number of children below the age of 11 years 
(4/402 children, 1%). Sera from nine children below the age of 11 years (9/402, 2.2%) tested 
positive for the treponemal antigen only. A higher percentage of sera from older children and 
adults tested positive for both antigens (15/217; 6.9%) as well as for the treponemal antigen 
alone (13/217; 6%) (Table 4.2).   
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Strongyloides spp. Sera from all children below 11 years of age and from the same 
representatives of older age groups as tested for antibodies against T. pallidum antigens were 
also analyzed for IgG titers against raw antigens of S. ratti by ELISA as a marker for exposure to 
S. stercoralis, since S. ratti antigen is cross-reactive with antibodies elicited by infection with 
this soil-transmitted helminth. The overall sero-positivity was low with 41/619 (6.6%) sera 
yielding equivocal test result and 33/619 (5.3%) testing positive. However, 3/170 (1.8%) 
children aged five years and below already tested positive (Fig 4.5, Table 4.2), demonstrating 
early exposure to infested soil. 
Schistosoma mansoni. Serum samples from all children <11 years and from the same 
representatives of older age groups as tested for antibodies against the other antigens were also 
analyzed for the presence of IgG against SEA and AWE of S. mansoni. Of the 619 sera, 29 
(4.7%) and 32 (5.2%) tested positive in the SEA and AWE ELISA, respectively. Most of the 
responders (n = 18; 2.9%) tested positive in both assays. While none of the children below the 
age of five tested positive against S. mansoni SEA, seven children aged five to ten had sero-
converted and 16/142 (11.3%) individuals aged between 11 and 20 had developed high anti-SEA 
antibody titers (Fig 4.6A, Table 4.2). A similar pattern was observed for the AWE with only one 
child aged below seven testing positive (Fig 4.6B, Table 4.2). The serum of this child was 
reconfirmed as being weakly positive by IFA (Fig 4.6C).  
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4.6 Discussion 
Since only a minority of individuals exposed to M. ulcerans develops clinical BU, sero-
epidemiological studies represent a valuable tool to assess the exposure of populations in BU 
endemic areas to the pathogen. In line with data obtained from previous sero-epidemiological 
investigations in BU endemic areas located in the Densu river basin of Ghana and in the Mapé 
river basin of Cameroon [11,15], we reconfirmed here for the population of the BU endemic 
Offin river valley that young children below four years of age are considerably less exposed to 
M. ulcerans than older children. In contrast, our serological data showed, as expected, that 
exposure to the mosquito transmitted malaria parasite P. falciparum and to soil-transmitted 
helminths of the genus Strongyloides takes place already in very young children, as indicated by 
an early development of humoral immune responses against these pathogens in some of the 
infants. The delay in exposure of M. ulcerans and the relatively abrupt onset are in stark contrast 
to the age-patterns for Plasmodium and Strongyloides. Contact with larvae-infested soil through 
faecal contamination is likely to be responsible for the observed early development of anti- 
Strongyloides serum IgG responses. Our results suggest that contact with M. ulcerans occurs 
outside the small movement range of infants, providing indirect evidence against mechanisms of 
transmission involving vectors or reservoirs present in the vicinity of the children‟s homes. 
However, our data do not exclude an involvement of insect vectors commonly found at the 
periphery of villages close to water contact sites. We recognize that the age distribution of anti- 
P. falciparum serum antibodies depends not only on the mode of transmission, but also on the 
transmission intensity [27,28]. While there is some evidence that mosquitos may be involved in 
transmission of M. ulcerans in south-eastern Australia [29,30], it is overall unlikely that they 
play a major role as vectors in African BU endemic settings. This assumption is also supported 
by previous molecular epidemiological studies showing that transmission of newly emerging 
genetic variants of M. ulcerans is geographically highly clustered [31,32].  
In Ghana schistosomiasis is mainly caused by S. haematobium and S. mansoni [33]. The egg 
forms of the parasite are shed into the environment via urine or faeces of an infected person. 
Through a complex life cycle involving an intermediate snail host, a healthy individual can be 
infected by coming into contact with water sources infested with invasive larvae [34]. Therefore, 
the risk of infection is related to water contact patterns. Peak prevalence is usually observed in 
school-aged children, but may be shifted to adulthood depending on the degree of endemicity in 
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a setting [35]. In the present study we observed in the Offin river basin the typical age 
distribution of Schistosoma exposure with children below the age of eight being significantly less 
affected than older children and young adults. This pattern was similar to the age distribution of 
exposure to M. ulcerans in the same population. While the mechanisms of infection by 
schistosomes and M. ulcerans are likely to be different, similarities in the age-dependent patterns 
of exposure may be related to changes in water contact patterns. It remains to be elucidated 
whether infection with M. ulcerans from an environmental reservoir takes place through skin 
lesions or via invertebrate vectors, such as aquatic insects. In addition, our data indicate that anti- 
M. ulcerans 18 kDa shsp IgG titers are relatively stable with only 2%, 3% and 8% of individuals 
followed up after 6, 12 and 18 months, respectively, having sero-converted or sero-reverted. A 
limitation of this longitudinal study was that study participants were followed up only once after 
6, 12 or 18 months. This study design was chosen to reduce dropout rates of study participants 
due to repeated blood drawings. Follow up of all study participants at three time points would 
have strengthened conclusions on the stability of antibody titers and in combination with 
environmental studies might have shed further light onto contact patterns of individuals with M. 
ulcerans.  
As part of our study we also analyzed serological responses of children below the age of 11 years 
to treponemal and non-treponemal antigens in order to assess exposure to T. pallidum subspecies 
pertenue, the causative agent of yaws, which is transmitted by direct contact with the fluid from 
the lesion of an infected person. In contrast to syphilis, caused by the closely related T. pallidum 
subspecies pallidum, yaws mainly affects children living in poor rural areas of tropical countries 
[36]. Traditionally, the recommended algorithm for the serological diagnosis of treponemal 
diseases includes a non-treponemal test for screening, and a treponemal test for confirmation. 
Non-treponemal tests detect antibodies to non-treponemal antigens such as cardiolipin and 
lecithin released from damaged host cells or lipoprotein-like material released from the 
treponemes. Due to the occurrence of false-positive reactions, treponemal test results based on T. 
pallidum antigen are required for a reconfirmation of non-treponemal tests [37].  
While eradication campaigns in the 1950s and 1960s by mass treatment of affected communities 
led to a drastic reduction of worldwide cases, yaws has lately re-emerged in Africa, Asia and the 
western Pacific [38] and Ghana was recently reported to be among the three most endemic 
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countries for yaws [39]. Official case notification rates were 32 and 383 per 100,000 population 
in 2010 for the Ashanti and Central regions, respectively [40], but underreporting is suspected. 
In this study antibodies to non-treponemal and treponemal antigens were detected in four of 402 
(1%) children below the age of 11, indicating active yaws transmission in the affected 
communities. Antibodies to the treponemal antigen only were found in 2.2% of the children. 
Since yaws and syphilis are serologically indistinguishable, the interpretation of test results in 
adolescents and adults would require careful clinical assessment. While  a recently published 
study in the Northern Region of Ghana has not found evidence of active yaws despite of 
continued case reporting [41], our data demonstrate evidence of ongoing yaws transmission in 
communities of the Offin river valley. There is an urgent need for more comprehensive data on 
the prevalence of yaws in Ghana to better implement mass drug administration programs. 
Comparative genome analyses, environmental studies, as well as serological and epidemiological 
studies of BU affected populations have in the last decades gradually broadened our knowledge 
of environmental reservoirs and probable infection routes of M. ulcerans. Future longitudinal 
sero-epidemiological and environmental studies over longer time periods combined with the 
monitoring of environmental contact patterns may be required to unravel mysteries of M. 
ulcerans transmission. 
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4.8 Figures 
 
Figure 4.1. Study area. Map of the Offin river basin in Ghana with selected study communities 
indicated as red dots. 
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Figure 4.2. Age distribution of anti- M. ulcerans 18 kDa shsp serum IgG titers. (A) Boxplots 
of OD values of 1:100 diluted serum samples tested in the anti- M. ulcerans 18 kDa shsp IgG 
specific ELISA by age group. The background cut-off value (OD<0.25) is indicated as a dotted 
line. The number of study participants for each age group (right y-axis) is visualized by grey dots 
connected by a grey line. (B) Sera obtained from a child participant (P1) at three different time 
points were tested for the presence of anti- M. ulcerans 18 kDa shsp serum IgG by Western Blot 
analysis. While the serum of the child tested positive at baseline, sero-reversion was observed 
after it had moved to a BU non-endemic community. A positive control serum (+) was included. 
The molecular weight standard (in kDa) is shown on the left of the blot. 
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Figure 4.3. Design and results of a longitudinal sero-epidemiological study. (A) Blood 
samples were taken in July 2013 from 1,352 inhabitants of the communities selected. All 
sampled individuals were followed up after either 6 (January 2014), 12 (August 2014) or 18 
(January 2015) months. IgG titers against the M. ulcerans 18 kDa shsp were determined in serum 
samples collected at baseline and compared to titers in samples collected at different time points 
(TP) after 6 (B), 12 (C) or 18 (D) months. A straight line was drawn to visualize deviations 
between time points analyzed. 
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Figure 4.4. Western blot analysis of anti- P. falciparum AMA-1 serum IgG responses in young children aged one (1), two (2) 
and three (3) years. A number of sera from children aged one and two years already contained serum IgG against recombinant P. 
falciparum AMA-1 protein, as determined by Western Blot analysis. The molecular weight standard (in kDa) is shown next to the two 
blots that are separated by a vertical black line.  
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Figure 4.5. Age distribution of anti- Strongyloides serum IgG titers. All sera from children 
below the age of 11 years as well as a subset of sera from older age groups were tested for the 
presence of anti- Strongyloides antigen IgG by ELISA. The grey and the black dotted line 
indicate the cut-off OD values for equivocal and positive test results, respectively. The number 
of study participants for each age group (right y-axis) is visualized by grey dots connected by a 
grey line. 
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Figure 4.6. Age distribution of anti- S. mansoni SEA and AWE serum IgG titers. All sera 
from children below the age of 11 years and a subset of individuals of older age groups were 
tested for the presence of IgG against S. mansoni SEA (A) and AWE (B) by ELISA. The grey 
and the black dotted line indicate the cut-off OD values for equivocal and positive test results, 
respectively. The number of study participants for each age group (right y-axis) is visualized by 
grey dots connected by a grey line. The serum of the only young child testing positive in the 
AWE ELISA was reconfirmed to be positive by IFA. The serum of this child as well as a 
negative control serum labelled C- and a positive control serum labelled C+ is shown (C).
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4.8.1 Supporting Figures 
 
Figure S4.1. Western Blot analysis of serum samples with a range of ODs in ELISA. 
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Figure S4.2. Detection of IgG against antigens of S. ratti iL3 (A), S. mansoni AWE (B) and S. mansoni SEA (C) in serum of 
parasitologically confirmed strongyloidiasis patients (A, Strongyloides), serum of parasitologically confirmed schistosomiasis 
patients (B and C, Schistosoma), negative control individuals (Blood donors) and patients with other parasitic infections 
(Other parasites). Each symbol shows a single serum sample. The corresponding cut-off is indicated in each graph by a horizontal 
line. The cut-off for the Strongyloides ELISA is 0.7, for Schistosoma AWE 0.30 and for Schistosoma SEA 0.60. n = number of 
samples. 
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Figure S4.3. Western Blot analysis of sera from all children <5 years for anti-18 kDa shsp IgG responses. 
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Figure S4.4. Western Blot analysis of sera from a number of children >4 years for anti- M. ulcerans 18 kDa shsp IgG 
responses. 
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4.9 Tables 
Pathogen Antigen ELISA cut-off (OD) 
  Negative Equivocal Positive 
S. mansoni SEA
a < 0.3 0.3 - 0.59 ≥ 0.6 
 AWE
b < 0.15 0.15 - 0.29 ≥ 0.3 
S. ratti raw antigen < 0.50 0.50 - 0.69 ≥ 0.70 
a
Soluble egg antigen, 
b
Adult worm antigen extract 
Table 4.1. Cut-off ODs for the S. mansoni and S. ratti ELISA. 
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Variables 
Age in years 
1
a
 2 3 4 5 6 7 8 9 10 11-20 21-
30 
31-40 41-
50 
51-
60 
>60 
n = Total population (%) 544 
(2.7) 
694 
(3.4) 
645 
(3.2) 
661 
(3.3) 
570 
(2.8) 
534 
(2.7) 
546 
(2.7) 
570 
(2.8) 
487 
(2.4) 
614 
(3.1) 
4,598 
(22.8) 
3,827 
(19) 
2,335 
(11.6) 
1,507 
(7.5) 
1,019 
(5.1) 
976 
(4.8) 
n = Participants (% of 
population) 
3 
(0.6) 
16 
(2.3) 
47 
(7.3) 
52 
(7.9) 
52 
(9.1) 
35 
(6.6) 
45 
(8.2) 
55 
(9.6) 
41 
(8.4) 
56 
(9.1) 
306 
(6.7) 
183 
(4.8) 
170 
(7.3) 
110 
(7.3) 
96 
(9.4) 
85 
(8.7) 
n = anti- M. ulcerans 18 
kDa shsp pos. (% of 
participants) 
0 (0) 0 (0) 1 (2) 3 (6) 2 (4) 2 (6) 3 (7) 8 
(15) 
3 (7) 9 
(16) 
49 
(16) 
34 
(19) 
43 
(25) 
30 
(27) 
25 
(26) 
20 
(24) 
n = anti- P. falciparum 
AMA-1 pos. (%) 
1/3 
(33) 
7/15 
(47) 
26/37 
(70) 
--- --- --- --- --- --- --- --- --- --- --- --- --- 
n = anti- 
T. 
pallidum 
pos. (%) 
Both 
antigens 
0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 1 (2) 1 (2) 5/142 
(4) 
1/13 
(8) 
1/14 
(7) 
1/15 
(7) 
1/14 
(7) 
6/19 
(32) 
 Treponemal 
antigen only 
0 (0) 0 (0) 0 (0) 0 (0) 3 (6) 0 (0) 1 (2) 1 (2) 1 (2) 3 (5) 4/142 
(3) 
2/13 
(15) 
0 (0) 2/15 
(13) 
0/14 
(0) 
5/19 
(26) 
n = anti- Strongyloides 
spp. pos. (%) 
0 (0) 1 (6) 1 (2) 1 (2) 1 (2) 1 (3) 0 (0) 1 (2) 2 (5) 4 (7) 15/142 
(11) 
0/13 
(0) 
1/14 
(7) 
3/15 
(20) 
1/14 
(7) 
1/19 
(5) 
n = anti- 
S. 
mansoni 
pos. (%) 
SEA
b
 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 1 (3) 1 (2) 3 (5) 0 (0) 1 (2) 16/142 
(11) 
2/13 
(15) 
1/14 
(7) 
2/15 
(13) 
0/14 
(0) 
1/19 
(5) 
 AWE
c
 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2) 2 (4) 0 (0) 2 (4) 15/142 
(11) 
2/13 
(15) 
4/14 
(29) 
3/15 
(20) 
0/14 
(0) 
2/19 
(11) 
 
Table 4.2. Population, study participants and serum positivity for the different antigens tested. Total numbers and percentages 
of the study population, study participants and the proportions of serum samples tested positive in the different serological tests are 
shown. 
a
no child below one year participated in the study, 
b
soluble egg antigen, 
c
adult worm antigen extract 
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4.9.1 Supporting Tables 
 
ELISA Sensitivity (%) (95% CI) Specificity (%) (95% CI) ROC AUC 
Strongyloides 95.0 (75.1-99.9) 84.3 (78.4-89.1) 0.95 
Schistosoma AWE 97.5 (79.2-99.9) 95.9 (92.2-98.2) 0.98 
Schistosoma SEA 80.0 (56.3-94.3) 92.4 (87.8-95.7) 0.96 
 
Table S4.1. Sensitivity and Specificity of ELISAs. The sensitivity and specificity with 95% CI 
(confidence interval) and the AUC (area under the ROC curve) values for the S. mansoni and S. 
ratti ELISAs are shown. 
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5.1 Abstract 
In recent years, comparative genome sequence analysis of African Mycobacterium ulcerans 
strains isolated from Buruli ulcer (BU) lesion specimen has revealed a very limited genetic 
diversity of closely related isolates and a striking association between genotype and geographical 
origin of the patients. Here, we compared whole genome sequences of five M. ulcerans strains 
isolated in 2004 or 2013 from BU lesions of four residents of the Offin river valley with 48 
strains isolated between 2002 and 2005 from BU lesions of individuals residing in the Densu 
river valley of Ghana. While all M. ulcerans isolates from the Densu river valley belonged to the 
same clonal complex, members of two distinct clonal complexes were found in the Offin river 
valley over space and time. The Offin strains were closely related to genotypes from either the 
Densu region or from the Asante Akim North district of Ghana. These results point towards an 
occasional involvement of a mobile reservoir in the transmission of M. ulcerans, enabling the 
spread of bacteria across different regions. 
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5.2 Author Summary 
Infection with Mycobacterium ulcerans causes the debilitating skin disease Buruli ulcer. Until 
today, transmission pathways and reservoirs of this emerging pathogen are not well understood. 
Generally, it is assumed that infection occurs after contact with potential environmental sources 
of M. ulcerans through puncture wounds or lacerations or via invertebrate vectors, such as 
aquatic insects contaminated with the bacteria. Comparative genome analyses of M. ulcerans 
strains isolated from patients living in the same BU endemic areas have revealed a close 
relationship between the genotype detected and the geographical origin, indicating that the 
reservoir of the pathogen is relatively fixed in space. In the present study, we report the co-
circulation of two distinct M. ulcerans clonal complexes in the same BU endemic area over 
space and time. Since members of these two clonal complexes were closely related to strains 
from either the Densu river valley or the Asante Akim North district of Ghana, we conclude that 
a mobile reservoir of M. ulcerans may be involved in the occasional spread of the bacteria across 
different regions.  
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5.3 Introduction 
Mycobacterium ulcerans is an emerging pathogen with elusive reservoirs and transmission 
pathways. It causes the devastating skin disease Buruli ulcer (BU) that mainly affects rural 
populations in West Africa [1]. M. ulcerans is a descendant of the fish and occasionally human 
pathogen Mycobacterium marinum [2], from which the new species has evolved through the 
acquisition of a plasmid encoding the enzymatic machinery for the synthesis of the macrolide 
toxin mycolactone [3]. From this common ancestor at least three different lineages or ecovars 
have evolved through genome reduction [4]. Clinical isolates from Africa belong to the classical 
lineage and differ from each other only in a very limited number of single nucleotide 
polymorphisms (SNPs) [4, 5], indicative for a highly clonal recent expansion of the pathogen in 
Africa. BU is characterized by a focal distribution of cases within endemic countries. Previous 
studies have revealed a strong association between genotype and the geographic origin of strains 
[4, 6, 7], speaking for the development of local clonal M. ulcerans complexes following the 
introduction of this pathogen into a new area. The limited genomic diversity found within these 
local clonal complexes is however sufficient for studies on the distribution of variants at a micro-
epidemiological level [8]. Since human-to-human transmission seems to be rare, findings point 
towards infection from a relatively localized environmental reservoir of the pathogen. In view of 
the association of BU outbreaks with stagnant and slow-flowing water bodies, a reservoir in the 
aquatic ecosystem is considered likely [9]. While in several African endemic areas a single 
unique clonal complex has been identified [4, 6-8], a recent comparative whole genome 
sequencing study of isolates from residents of the Asante Akim North district of Ghana showed 
for the first time the concurrent presence of two distinct clonal complexes within one BU 
endemic area [10].  
Within the framework of a comprehensive genome analysis of clinical M. ulcerans isolates from 
Ghana, we analyzed genomes of a limited number of strains from the Offin river valley and 
equally observed a co-existence of two clonal complexes. 
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5.4 Methods 
Ethics statement 
Ethical approval for the study was obtained from the institutional review board of the Noguchi 
Memorial Institute for Medical Research (Federal-wide Assurance number FWA00001824). 
Written informed consent was provided by all study participants. 
 
Study area and M. ulcerans isolates 
In an exhaustive active BU case search conducted in 2013 and a subsequent continuous 
monitoring of cases over a 17-months period in 13 randomly selected communities located in the 
historically highly BU endemic Offin river valley, an  unexpectedly low prevalence of BU was 
revealed with only 11 laboratory-confirmed cases identified [11]. Two M. ulcerans strains that 
could be isolated from two of the 11 patients, as well as three M. ulcerans strains isolated in 
2004 from lesions of two BU patients residing in the valley were analyzed in this study (Table 
5.1). In addition, we included 48 M. ulcerans isolates from patients residing in BU endemic areas 
located in the Densu river valley of Ghana, which were part of a previous SNP typing study [8]. 
All M. ulcerans strains were subjected to whole genome sequencing.  
 
DNA extraction and whole genome analysis 
Genomic DNA was extracted from M. ulcerans cultures by phenol-chlorophorm extraction and 
ethanol precipitation as described previously [12]. Multiplexed genomic DNA libraries were 
prepared and sequenced on an Illumina HiSeq 2000 on 75-bp paired-end runs [13]. Illumina 
reads were aligned to the complete reference genome of M. ulcerans strain Agy99 (GenBank 
accession number CP000325.1) with an insert size between 50 and 400 bp using BWA version 
0.7.10. SNPs were identified using SAMtools [14] as described [15] and were filtered for a 
minimum mapping quality of 30 and a quality cutoff of 75%. SNPs called in repetitive regions of 
the M. ulcerans reference genome (737,280 bp) were excluded from the analysis and only the 
SNPs mapped in the core genome (4,894,326 bp) were used to construct the phylogenetic trees.  
 
Phylogenetic analyses 
Maximum-likelihood phylogenetic analysis was performed using RAxML [16] on the alignment 
of identified SNPs from across the Ghanaian genomes sequenced here, together with genomes 
Chapter 5 – Local genetic diversity of M. ulcerans   
 
113 
 
sequenced in previous studies [4, 10, 17]. Additional strains isolated from BU patients from 
other regions of Ghana and from Benin and Australia were included in the analysis to provide a 
comprehensive genetic context for the analysis of genetic diversity among the Offin and Densu 
isolates.  
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5.5 Results/Discussion 
Phylogenetic analysis demonstrated the expansion of a single clonal complex in the Densu river 
valley (Fig 5.1). This complex has diversified substantially, but still forms a separate cluster, 
distinct from other African local clonal complexes (Fig 5.2 and 5.3). When compared to the 
second branch of the classical lineage of M. ulcerans - isolates from Australia - it is evident, that 
all African isolates are genomically extremely closely related (Fig 5.2). In contrast to the 
observation of a single clonal complex in the Densu river valley, our analysis revealed for the 
Offin river valley the presence of members of two distinct clonal complexes (Fig 5.3). Two Offin 
isolates (NM031 and NM997) were closely related to isolates from the Densu river valley of 
Ghana (Fig 5.1 and 5.3). The other three Offin isolates (NM022B, NM022D and NM972) – 
separated from the two Densu-like Offin strains by 29 SNPs – clustered with strains (belonging 
to a clonal complex designated Agogo-1; [10]) from the Asante Akim North district in the 
Ashanti region of Ghana (Fig 4.3). Intra-genotype average diversity was low with 12 and 17 
identified SNPs among Densu-like and Agogo-1-like Offin isolates, respectively. Not a single 
SNP difference was found between the genomes of two strains (NM022B and NM022D) isolated 
from two different lesions of the same patient. In a next step, we combined the phylogenetic 
analysis of the Offin isolates with information on the residence of the patients within the river 
valley and the year of strain isolation (Fig 5.4). In both 2004 and 2013 one member each of the 
two clonal complexes, isolated from BU patients resident in different communities was found. 
Due to the limited number of isolates and missing details on the travel history of the BU patients 
from which these strains have been isolated, no firm conclusions could be drawn concerning the 
apparent lack of geographical clustering. However, the data revealed a co-circulation of two 
distinct M. ulcerans clonal complexes in the Offin river valley over space and time.  
In contrast to the remarkably strong link between genotype and geographical origin of clinical M. 
ulcerans isolates reported in previous genotyping studies conducted in African BU endemic foci 
[6-8], two distinct M. ulcerans clonal complexes were recently found to co-exist in the Asante 
Akim North district of Ghana among strains isolated within the short time frame of two years 
and an area of only 30km
2
 [10]. It was concluded that M. ulcerans genotypes might be spread 
across larger areas, suggesting the presence of a rather mobile reservoir of infection in addition 
to the postulated more focalized aquatic niche environment typically associated with the 
pathogen [9]. In this context, recent data indicated that M. ulcerans is able to persist for several 
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months in underwater decaying organic matter [18], possibly as a commensal in protective 
aquatic host environments [19-21]. While the specific factors favoring the persistence of M. 
ulcerans in the environment and its transmission are yet to be explored, a complex interplay 
between environmental factors as well as biotic and abiotic drivers is assumed [22, 23]. 
Reductive genome evolution of M. ulcerans speaks for niche adaptation [17].  
In the present study we revealed the co-existence of both Densu-like and Agogo-1-like M. 
ulcerans genotypes in communities along the Offin river at two time points separated by ten 
years. Our data thus show that co-existence of clonal complexes in one BU endemic area may 
prevail over longer time periods. A mobile mammalian host, allowing the bacteria to replicate 
and to be shed to the environment, that way forming a reservoir [18] from which humans may be 
infected by unknown mechanisms, could be the missing link explaining the spread of M. 
ulcerans from an established BU endemic region to a new area. However, as demonstrated here 
by the presence of only a single clonal complex in the Densu river valley, the exchange of 
genetic M. ulcerans variants between BU endemic areas appears to be an extremely rare event.  
While in Australia possums have been identified as a host for M. ulcerans [24], another line of 
evidence points to the involvement of humans with chronic ulcerative BU lesions in the spread 
of the bacteria in African BU environments. Extensive whole-genome sequencing studies are 
required to further unravel the evolutionary history and population structure of M. ulcerans in 
Africa. 
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5.6 Figures  
 
Figure 5.1. Phylogenetic reconstruction of M. ulcerans isolates belonging to the clonal 
complex circulating in the Densu river valley of Ghana. Maximum-likelihood phylogenetic 
tree based on 292 variable nucleotide positions across M. ulcerans isolates produced by RAxML. 
A total of 48 M. ulcerans isolates from the Densu river valley and two isolates from the Offin 
river valley were shown to belong to the same clonal complex that has diversified substantially 
over time. The tree was rooted using M. ulcerans strain Agy99 as an out-group. Bootstrap values 
are shown along the branches. 0.01 = scale for genetic distance. 
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Figure 5.2. Phylogenetic reconstruction of M. ulcerans isolates belonging to the classical 
lineage (Australian and African strains). Maximum-likelihood phylogenetic tree based on 
11,194 variable nucleotide positions across M. ulcerans isolates by RAxML. M. ulcerans isolates 
from the Offin and Densu river (one representative each of the previously identified SNP 
haplotypes [8]) valleys were placed in a broader genomic context. The tree was rooted using M. 
ulcerans strain Mu 06-3844 (isolate from a fish farm in Belgium) as an out-group. Bootstrap 
values are shown along the branches. 0.02 = scale for genetic distance. 
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Figure 5.3. Phylogenetic reconstruction of closely related M. ulcerans isolates from 
different BU endemic areas of Ghana and from Benin. Maximum-likelihood phylogenetic 
tree based on 776 variable nucleotide positions showing relations between the strains at a higher 
resolution than in Fig. 5.2. Bootstrap values are shown along the branches. 0.002 = scale for 
genetic distance.  
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Figure 5.4. Geographical distribution of M. ulcerans isolates from the Offin river valley. 
Map of the Offin river basin, depicting the residences of BU patients from whom the strains have 
been isolated in 2004 (red) and 2013 (green). The background map was created using the 
ArcMap program in ArcGIS v.10.0 software. 
 
 
.
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5.7 Tables 
 
Isolate ID Year of isolation Village of residence* Genotype Average 
sequence 
coverage 
NM022B 2004 Atuntuma Agogo-1  101.54 
NM022D 2004 Atuntuma Agogo-1  88.304 
NM031 2004 Subin Densu  91.743 
NM972 2013 Treposo Agogo-1  90.481 
NM997 2013 Ntobroso Densu 94.425 
 
Table 5.1. M. ulcerans isolates sequenced in this study. 
*see Figure 5.4. for location along the Offin river
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6.1 Abstract 
Hepatitis B virus (HBV) infections account for approximately 780,000 deaths per year, most of 
which occur in the developing world. Co-infection with HBV and hepatitis delta virus (HDV) 
may lead to the most severe form of viral hepatitis. In Ghana, knowledge on the prevalence of 
HBV and HDV in the general population is scanty and the few genetic analyses of the prevailing 
HBV genotypes are dating back more than a decade. In the present study, 1,323 serum samples 
from individuals living in a rural area (Offin river valley) of Ghana were analyzed for the 
presence of the hepatitis B surface antigen (HBsAg). Positive sera were subsequently tested for 
the presence of anti-HDV antibodies. A total of 107 (8%) sera were HBsAg positive with an 
8.4% prevalence of anti-HDV antibodies among the HBsAg positives. Phylogenetic analysis, 
based on HBV pre-S/S sequences, attributed all 52 typable samples to genotype E. All belonged 
to serotype ayw4. While 19 sequences clustered with those from a number of African countries, 
the other 33 formed a separate cluster distinguished by an intergroup mean distance of 1.5% 
from the pan-African HBV/E cluster. Successful implementation of HBV vaccination in the 
region was reflected by the low HBsAg carrier rate of 1.8% among children ≤11 years.  
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6.2 Introduction 
Despite the availability of effective hepatitis B virus (HBV) vaccines, the global burden of 
hepatitis B remains high, with an estimated 240 million chronically infected individuals and 
about 780,000 deaths from cirrhosis and hepatocellular carcinoma each year [1]. Transmission of 
HBV can occur through diverse routes including perinatal, sexual and household contact, or by 
unsafe injections. The HBV genome is a circular, partially double-stranded DNA, approximately 
3.2 Kb in length, which contains four partially overlapping open reading frames, encoding the 
polymerase (P), the surface proteins (pre-S1/pre-S2/S), the core antigen and the soluble antigen 
„e‟ (preC/C), and the regulatory protein (X), respectively [2]. To date, HBV isolates have been 
classified into eight confirmed (A to H) [3-7] and two tentative (I and J) [8, 9] genotypes, based 
on a divergence of >7.5% in the whole genome, or >4% in the S gene sequence. In recent years it 
has become increasingly evident that a distinct global geographical distribution of HBV 
genotypes is a major factor responsible for differences observed in clinical manifestations and 
response to antiviral treatment and vaccination [10-12], emphasizing the importance of 
genotyping studies to identify the locally prevailing genotypes.  
While hepatitis B is hyper-endemic in sub-Saharan Africa, underreporting, due to limited access 
to healthcare and lack of knowledge on the infection, hinder precise accounts on the actual 
burden, particularly in remote areas [13]. Previous studies have shown that HBV genotype E 
(HBV/E) is by far the most prevalent in West and Central Africa [14-17], spreading in a vast 
crescent with a span from Senegal to Namibia. The other two dominating genotypes circulating 
in Africa, are found mainly in Southern, Eastern and Central Africa (HBV/A) [13], and in 
Northern Africa (HBV/D) [18-20]. A recent emergence of genotype E, within the last 130 years, 
has been proposed, based on the fact that this genotype is restricted to the African continent and 
shows the lowest diversity as compared to other genotypes [14, 21, 22]. However, the origin and 
evolutionary history of HBV/E remain unclear. While recent studies in Ghana have investigated 
HBsAg prevalence rates within specific groups, such as HIV patients (13-17% [23, 24]), 
pregnant women (11-13% [25-27]), blood donors (7.5-15% [28-31]), or prison inmates (17-
25.5% [32, 33]), knowledge of HBV prevalence in the general population is limited. Although it 
has been reported that HBV/E is the prevailing genotype in historical specimens from Ghana [34, 
35], detailed information on the current population structure of HBV in the country is lacking.  
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An estimated 15-20 million individuals worldwide are co-infected with HBV and hepatitis delta 
virus (HDV), representing the most severe form of chronic hepatitis [36, 37]. HDV is a defective 
virus requiring hepatitis B surface antigen (HBsAg) to survive, and is principally transmitted by 
the parenteral route. Except for a recent study reporting an 11.3% seroprevalence of HDV 
infection in a small number of patients with HBV-related liver diseases in Accra [38], data on the 
prevalence of HDV in Ghana are lacking. 
The objective of the present study was to investigate the prevalence and genomic diversity of 
HBV in the general population of the Offin river valley in Ghana.  
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6.3 Methods 
Ethics statement 
Ethical approval for the study was obtained from the institutional review board of the Noguchi 
Memorial Institute for Medical Research (Federal-wide Assurance number FWA00001824). 
Written informed consent was provided by all study participants or, in the case of children, by 
their parents or guardians. 
 
Design of the study 
The Offin river runs through two (Ashanti and Central) of the ten Ghanaian regions (Fig 6.1), 
covering a total of 11 health districts. In a preceding study, we investigated the epidemiology of 
the tropical skin disease Buruli ulcer in selected communities of the Offin river valley of Ghana 
by conducting an exhaustive household survey in 2013 [39]. Based on the demographic 
information collated for 20,390 residents of 13 communities located in seven health districts 
(Table 6.1) spread along the Offin river (Fig 6.1), we grouped the population of each community 
by age and randomly selected from all of the age groups a total of 1,560 residents (120 per 
community). Of these 1,560 individuals, 1,352 consented to donate blood for sero-
epidemiological studies of multiple pathogens [40]. 
In the present study, we analyzed 1,323 of the 1,352 serum samples retrospectively for the 
presence of HBV and HDV markers. The distribution of study participants by age group and 
community of residence is shown in Fig S6.1. Moreover, we re-evaluated general information on 
the communities, as well as study questionnaires administered in 2013 to 20,390 inhabitants of 
the 13 study communities, to extract demographic information relevant for the study of hepatitis 
in this region, including road networks, social and health system infrastructure and travel habits.  
 
Serological analysis  
A total of 1,323 retrospective blood serum samples stored at -80°C were analyzed in the present 
study. 
Detection of HBsAg 
Serum samples were screened for the presence of HBsAg by immunochromatography 
(Advanced Quality ONE STEP HBsAg Test Strip, Intec Products Inc., China) according to the 
manufacturer‟s instructions. Briefly, we applied 100 µl of serum onto the test strips and recorded 
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the presence or absence of a red band on the nitrocellulose strip after 15 minutes. In order to 
validate the performance of this rapid test, we analyzed 88 serum samples in parallel by ELISA 
using the HBsAg BioAssay ELISA Kit (US Biological, Salem, USA) in strict accordance to the 
manufacturer‟s instructions. The same results were obtained in both tests, with three samples 
yielding a positive result. 
Detection of anti-HDV antibodies 
The HDV antigen (HDAg) can elicit a specific antibody response in infected individuals. We 
analyzed all HBsAg-positive serum samples for the presence of anti-HDV antibodies by ELISA 
(ETI-AB-DELTAK-2, DiaSorin, Italy) according to the manufacturer‟s instructions. 
 
Nucleic acid extraction, HBV PCR amplification and nucleotide sequencing 
Total nucleic acids were extracted from 200 µl of HBsAg-positive serum samples using the High 
Pure Viral Nucleic Acid Kit (Roche, Mannheim, Germany) according to the manufacturer's 
instructions. Nucleic acids were re-suspended in 50 µl of TE buffer and 3 µl were applied in the 
PCR assays. 
Amplification of the HBV pre-S/S region was attempted by a semi-nested PCR assay, in which 
samples negative in the first round, were subjected to a second round of PCR. In both reactions, 
PCR amplification of extracted DNA was performed with 2.5 units of FirePolTaq-Polymerase 
(Solis BioDyne, Tartu, Estonia), FirePol buffer, 2 mM MgCl2 and 0.4 mM dNTPs with 1.8 µl of 
10 µM forward and reverse primers each in a total volume of 30 µl. While primer pairs PS1 (5‟-
CCATATTCTTGGGAACAAGA-3‟) and P3 (5‟-AAAGCCCAAAAGACCCACAA-3‟) were 
applied in the first PCR round to generate a product of 1,405 bp, P3 was replaced by S2 (5‟-
GGGTTTAAATGTATACCCAAAA-3‟) in the second round, amplifying a product of 1,227 bp. 
PCR reactions were carried out in a Gene Amp PCR System 9700 PCR machine (Applied 
Biosystems) and thermal conditions for PCR amplifications included an initial denaturation step 
at 94°C for 5 min followed by 32 cycles at 94°C for 30 s, 57°C for 30 s and 72°C for 1 min and a 
final extension step, 72°C for 10 min. PCR products were analyzed on 1% agarose gels. 
Nucleotide sequencing was accomplished using primers PS1, PS8 (5‟-
TTCCTGAACTGGAGCCACCA-3‟), PS4 (5‟-ACACTCATCCTCAGGCCATGCAGTG-3‟), 
S2, S4 (5‟-TGCTGCTATGCCTCATCTTCT-3‟) and P3 for the larger sequence, and PS1, PS8, 
PS4 and S2 for the smaller sequence. We also amplified a smaller fragment spanning the S gene 
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by applying the same PCR procedure using primers PS1a (5‟-GGAAAACATCACATCAGGAT-
3‟) and P3 for the first round of PCR and primers PS1b (5‟-AAAATTCGCAGTCCCCAACC-3‟) 
and P3 for the second round. In this case, the same primers were used for nucleotide sequencing. 
PCR products were purified using the Nucleo Spin Extract II Kit (Macherey-Nagel, Düren, 
Germany) and sequenced at Macrogen Inc., Europe (Amsterdam, the Netherlands). 
 
Statistical analysis  
All statistical analyses were carried out with GraphPad Prism version 6.0 (GraphPad Software, 
San Diego, CA) and Stata 12 (Statacorp 2011 statistical software Release 12. College Station, 
TX: StataCorp LP). The associations between categorical variables were assessed using 
Pearson‟s Chi square test or Fisher‟s exact test. The level of statistical significance was set 
P<0.05. 
 
Phylogenetic analysis and inference of serotypes 
Genotyping of HBV was performed by analyzing a partial sequence of the genome - the pre-S/S 
region - consistent with genotyping of the full genomic sequence. Nucleotide sequences of the 
pre-S/S or S genes were aligned using the ABI Prism AutoAssembler, version 1.4.0 (Perkin-
Elmer, Waltham, MA). Maximum-likelihood phylogenetic analysis was performed using the 
Kimura 2-parameter model [41] of MEGA version 6.0 [42]. Previously published mutations in 
the S region associated with “escape” or with diminished antibody binding were predicted using 
the Geno2pheno[HBV] online tool at http://hbv.geno2pheno.org/index.php. The 
Geno2pheno[HBV] tool was also used to predict drug resistance mutations in the part of the 
reverse transcriptase open reading frame that overlaps with that of S. Genetic distances were 
estimated using MEGA 6.0 tools [42].  
HBV serotypes were predicted based on the amino acids present at either three or five known 
positions (122, 160, 127, 159 and 140) within the S gene [43] using the web-based HBV 
Serotyper Tool that can be accessed at http://hvdr.bioinf.wits.ac.za/SmallGenomeTools [44]. 
 
Nucleotide sequence accession numbers 
The HBV/E sequences determined in this work have been deposited in the 
DDBJ/GenBank/EMBL database (accession numbers KU522251-KU522302). 
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6.4 Results 
Demographic characteristics of the study population and participants  
In order to gain insight into the burden of hepatitis B and D infection in the general population of 
the Offin river valley in Ghana, we analyzed serum samples from a representative proportion of 
individuals living in 13 selected communities located up-, mid- and downstream along the Offin 
river (Fig 6.1). Of the total of 20,390 residents of these communities, 1,323 individuals (from 71 
to 123 inhabitants per community) aged between 1 and 90 years (mean age 25.3 ± 19.5 years, 
median 19 years) participated in the study (Fig S6.1), with 59% (n = 781) being females and 
41% (n = 542) being males (Table 6.1). The 13 communities belonged to seven health districts, 
all of which reported to have introduced the pentavalent diphtheria, tetanus, pertussis, 
Haemophilus influenzae type B, hepatitis B (DPTHH) vaccine in 2002 following the WHO 
Expanded Program on Immunization (EPI). 
As listed in Table 6.1, the characteristics of the 13 selected study communities varied, ranging 
from small settlements located within farmlands and lacking basic social amenities and a good 
road network, like Krakrom, to larger communities, like Dominase, which in addition to having 
all the social amenities, is connected to the district capital by a good road network. Almost 40% 
(7,812/20,390) of the general population reported to have travelled out of their communities in 
the past three months with the majority of those (n = 4,659) reporting to have resided in a 
metropolitan town for at least one day. While 80% (16,262/20,390) of the inhabitants were 
Akans, the other 20% were composed of Ewe, Mole, Ga/Ada, Guan, Gruma, Grusi, Mande, 
Mamprusi, Kussasi and others [39]. There were also 37 (0.18%) nationals of other West African 
countries, namely Benin (n = 2), Burkina Faso (n = 7), Côte d'Ivoire (n = 4), Togo (n = 4), Niger 
(n = 12) and Nigeria (n = 8). 
 
Prevalence of HBsAg and anti-HDV antibodies in the Offin River Valley population 
One hundred and seven (8.1%) of the 1,323 serum samples tested were HBsAg positive, with a 
nearly equal gender distribution of 7.7% (n = 60) in females and 8.7% (n = 47) in males (p = 
0.516). There was no significant association between ethnic groups and positivity for HBsAg (p 
= 0.609), but a high variation in prevalence (1.9% to 14.9%) between communities, which was 
however not associated with the quality of road or social infrastructure of the community (Table 
6.1). The age distribution of HBsAg positive individuals in relation to the total number of study 
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participants is depicted in Fig 6.2. HBsAg was detected in a significantly (p < 0.001) higher 
proportion of individuals aged above 11 years (11.1%; 99/890) than in children aged 11 years or 
less (1.8%; 8/433). Prevalence of HBsAg-positivity was low (2%; 2/101) in the age group ≥60 
years. 
Nine (8.4%) of the 107 HBsAg carriers were tested positive for anti-HDV antibodies. All nine 
positive sera (ABUS036, BUDS073, NKS076, NKS089, NKS100, TNS007, TNS058, TNS088 
and WMS021) were from residents of five study communities (Table 6.1) located mid- and 
downstream along the Offin river (Fig 6.1). 
 
Phylogenetic analysis of HBV isolates circulating in the Offin river valley 
HBV DNA could be amplified from 66/107 (62%) samples positive for HBsAg. Phylogenetic 
analysis was performed with pre-S/S sequences obtained from 52 of the 66 PCR products. The 
remaining 14 sequences showed high similarity to the other sequences obtained, but each of 
them contained several ambiguous nucleotide positions (suggesting mixed infections with more 
than one genetic HBV variant), and the sequences were therefore not included in the 
phylogenetic analysis.  
The 52 sequences (obtained from residents of 12 of the 13 study communities) were compared 
with representative sequences of the HBV isolates from genotypes A-J retrieved from GenBank 
(see accession numbers in the legend of Fig 6.3). The resulting phylogenetic reconstruction was 
rooted by including the sequence of a virus isolate from a Woolly monkey (WMHBV) as an out-
group (GenBank accession number AY226578). All Offin river valley sequences clustered with 
those of HBV/E strains from Ghana and other countries included in the alignment (Fig 6.3).  
A more detailed resolution of the population structure of HBV from the Offin river valley was 
achieved by aligning the sequences exclusively with other HBV/E sequences. The overall mean 
genetic distance among the 52 sequences of this study was 1.2% based on the pre-S/S region, and 
0.6% when only the S region was analyzed. Interestingly, maximum likelihood reconstruction, 
based on the complete pre-S/S region, revealed the presence of two separate genetic clusters, 
with an intergroup mean distance of 1.5%. While 19 sequences grouped with HBV/E strains 
from Ghana, Madagascar, Benin, Côte d'Ivoire, Nigeria, and Niger (pan-African cluster), the 33 
others formed a separate cluster that did not contain any sequence other than those from the 
Offin river valley (Fig 6.4). Representatives of the Offin cluster were from 11 of the 13 study 
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communities, while sequences belonging to the pan-African cluster originated from nine 
communities (Table S6.1). However, no significant association was found between sequence 
origin and affiliation to one of the two different clusters (p = 0.589). The mean genetic distance 
of the 19 sequences attributed to the pan-African cluster was 1.6%, compared with 0.7% among 
the 33 belonging to the Offin cluster. Characteristics of all individuals for which sequence 
information is available are listed in Table S6.2. 
 
Detection of relevant HBV signature motifs, deletions and other mutations in the pre-S/S 
region 
The deduced amino-acid sequences of the pre-S/S region were highly conserved among the 52 
HBV isolates analyzed in this study. All of them had a single amino acid deletion at the N-
terminus of the pre-S1 region (residue Met12 in sequences of other genotypes), leading to a pre-
S1 region of 118 amino acids in length, a feature characteristic for HBV/E strains [45]. 
Moreover, all sequences showed the genotype E pre-S1 amino acid signature motif 
Leu3SerTrpThrValProLeuGluTrp11. Amino acid residue Met83, that has been reported to 
introduce a new translational start codon in the pre-S1 region [45], was present in all but one 
(NBUS067) sequence. The emergence and selection of new pre-S variants is a common event in 
chronically HBV infected patients. Genetic defects are usually due to in-frame deletions of 
different sizes in the carboxy terminus of the pre-S1 region, or are caused by substitutions at the 
start codon of the pre-S2 region with complete abolishment of M protein synthesis [46]. Here, 
deletions of 27 and 25 amino acids (sample PKS034) and of six amino acids (PKS077) were 
detected in the pre-S region. Moreover, substitutions leading to the loss of the pre-S2 start codon 
(Met119) were detected in three sequences (NBUS058, NKS010 and WMS009). 
The S region is particularly conserved. It has been reported that the majority of the HBV/E 
isolates from South-West Africa contain an Ile57 residue, while those from North-West Africa 
show a Thr57 residue [45]. In this study, 51 Ghanaian sequences had a Thr residue, while only 
one (TNS014), belonging to the pan-African cluster, had an Ile at that position.  
Neutralizing antibodies induced by immunization against HBV are mainly directed against 
conformational epitopes of the major antigenic „a‟ determinant, spanning amino acids 124-147 of 
the S region [47]. A number of amino acid substitutions within this region, mainly between 
positions 137 and 147, have been described as vaccine or immune escape mutants [48]. In two of 
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the HBV sequences obtained in this study (MFS048 and TNS091), we detected the mutation 
sS143L, previously identified in an HBsAg escape mutant [49]. No known mutations in the S-
overlapping reverse transcriptase region, relevant for phenotypic resistance to five antiretroviral 
drugs (Lamivudine, Adefovir, Entecavir, Tenofovir and Telbivudine) were found.  
Two nonsense mutations of the S gene - one at position Leu216 (sLeu216*) affecting six HBV 
sequences (PKS034, TNS014, WMS009, BUDS073, TNS055 and TNS065), and the other at 
position Trp182 (sTrp182*) found in sequence BUDS005 - were detected, resulting in a C-
terminal truncation of the S protein in these strains. All deletions and substitutions described 
above are shown in Table 6.2. 
 
Serotype distribution of HBV in the Offin river valley 
According to the previously described amino acid sequence algorithms [43] R
122
, K
160
, L/I
127
 
(found in 94% of the sequences) and R
122
, K
160
, P
127
, G
159
, S
140
 (detected in the remaining 6%), 
all the 52 HBV sequences of this study were classified as HBV serotype ayw4. 
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6.5 Discussion 
Analysis of sera collected from inhabitants of 13 communities located in the Offin river basin of 
Ghana by a rapid strip assay revealed a high (>8%) HBsAg prevalence in the rural population 
under study. Since it is known that the sensitivity of rapid strip assays may be lower than that of 
more complex enzyme immunoassays [50], we validated the performance of the rapid test used 
by analyzing a subset of samples in parallel by an ELISA. Both assays yielded identical results 
for the 88 samples tested. Antibodies to HDV were found in the serum of more than 8% of the 
107 HBsAg carriers. This frequency of co-infection is similar to that observed in a recent study 
conducted in Accra, where a HDV sero-prevalence of 11.3% was found among 53 patients with 
HBV-related liver disease [38]. HBV can be transmitted horizontally by exposure to infected 
blood and various other body fluids or vertically by spread from mother to child at birth, with the 
majority of the children infected before the age of 6 months becoming chronic carriers [1]. In our 
study population we observed a significantly lower HBsAg carrier rate (1.8%) among children 
≤11 years than in the older population (11.1%), coinciding with the 11 year period since when 
Ghana has introduced HBV vaccination with the pentavalent DPTHH vaccine. These data tend to 
confirm that HBV vaccination is effectively implemented in the Offin river valley. In a recent 
study performed in rural areas of Ghana, an at least 95% coverage for all three doses of DPTHH 
by the end of the first year of life was reported. However, immunizations suffered from poor 
timeliness, with substantial inequity across educational and socio-economic classes, due to weak 
supply chain management and poor access to health services [51]. Therefore, more detailed 
studies are needed to assess the efficacy of HBV vaccination in Ghana. While the administration 
of the hepatitis B vaccine at birth or in early childhood has been effective in reducing the 
incidence of the disease in many endemic regions [52, 53], immunization programs will not 
benefit patients already chronically infected with HBV. The low HBsAg carrier rate in the age 
group ≥60 years may be related to the higher mortality rate in elderly individuals with viral 
hepatitis [54, 55], which has been attributed in part to a higher prevalence of co-morbidities. 
Since HBsAg carriage was high in adolescents and adults, our data demonstrate that public 
health efforts are required to screen and subsequently ensure access to treatment, particularly for 
persons suffering from cirrhosis or advanced stages of liver disease. Moreover, additional needs 
for the management of concurrent or sequential infection with HBV and other viruses such as 
HIV, HCV and/or HDV - often associated with more severe and progressive liver disease and a 
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higher incidence of cirrhosis and hepatocellular carcinoma - should be addressed. These include 
the identification and initial treatment of the dominant virus followed by monitoring of the co-
infecting virus [56]. Another essential aspect to be considered in the management of hepatitis is 
that populations with high HBV prevalence live in regions also endemic for mycobacterial 
infections such as tuberculosis, leprosy and Buruli ulcer. Special caution has to be paid when 
treating individuals with advanced stage liver disease with standard anti-mycobacterial regimens 
in order to avoid drug-induced hepatitis [56-58]. In this context, drug-induced liver injury has 
been reported to be three- to six-fold higher in persons infected with HBV, HCV or HIV who are 
receiving anti-tuberculosis drugs, due to hepatotoxicity of isoniazid, rifampicin and 
pyrazinamide [59]. 
Until today only a limited number of HBV genotyping studies have been conducted in Ghana. 
Two reports have indicated the exclusive presence of genotype E in samples collected more than 
15 years ago [34, 35]. Strains analyzed in these studies came from targeted groups, such as 
pregnant women, HIV seropositive individuals and blood donors. In the present study, we 
provide the first molecular study of HBV from carriers resident in rural communities of the Offin 
river valley of Ghana. Although more than a decade has passed, and the co-circulation of two 
genotypes, namely A and E, has been reported in other West African countries [35], our 
phylogenetic analysis, based on the pre-S/S sequence of 52 HBV samples, showed that all of 
them belonged to genotype E, and all were predicted to belong to serotype ayw4. However, two 
separate E ayw4 genetic clusters were found. The Offin cluster, comprising 33/52 sequences 
obtained from individuals living in 11 of the 13 study communities, showed a low diversity with 
an intra-group mean distance of only 0.7%. With an intra-group mean distance of 1.6%, the 19 
sequences belonging to the pan-African cluster were more diverse, and originated from nine 
different communities, including Akomfore, Krakrom and Mfantseman, which are the three most 
remote communities. The Offin river basin has been a focus of small scale gold mining for many 
centuries and has produced more gold than any other river system in Ghana [60]. Over the years, 
there has been up-scaling of mining activities coupled with the influx of artisans from other 
regions of Ghana, as well as of citizens from other countries. During our exhaustive household 
survey in the Offin river valley, we encountered a number of nationals from other West African 
countries, particularly from Niger, Nigeria and Benin, representing one potential source for the 
introduction of new HBV genetic variants into the river basin.  
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In general, the very low diversity of the 52 pre-S/S region (1.2%) and S region (0.6%) sequences 
of this study is in line with previously published data reporting a strikingly low genetic diversity 
of HBV/E [14, 21]. Analysis of 610 S region sequences has revealed a mean genetic diversity of 
0.8% for HBV/E as compared with a 2.1% diversity for 167 African HBV/A sequences [21]. The 
apparently relatively recent emergence of genotype E in Africa is contrasted by the excessive 
spread of this genotype throughout West Africa. While this has led to hypotheses on a more 
efficient mechanism of transmission, as compared to genotype A, it has been speculated in a 
recent report that historical mass vaccination campaigns with unsafe injection needles may have 
caused the current high prevalence rates of HBV/E throughout sub-Saharan Africa [21]. As a 
result of the increasing selection pressure caused by widespread HBV vaccination, 
immunotherapy and chronic HBV infections, various escape mutations in the HBsAg gene have 
been reported. Neutralizing antibodies induced by immunization are targeted against the 
conformational epitopes of the „a‟ determinant of the surface antigen [47]. Mutations within this 
determinant may affect the binding of anti-HBs antibodies, allowing for the replication of the 
virus in vaccinated individuals, and pose a challenge to immunoassay detection. Although only 
individuals testing HBsAg positive were included in the present study, we identified the 
previously described [49] Ser143Leu substitution in the „a‟ determinant. The codon 143 mutation 
has been reported to cause false negative results in some commercial HBsAg immuno-assays 
[61]. These data stress the importance of using HBsAg assays with a high sensitivity, in 
particular for the screening of blood bank donors. In addition, we detected two nonsense 
mutations in several HBV sequences at positions Leu
216
 (sLeu216*) and Trp
182
 (sTrp182*) of the 
S gene, for which potent oncogenic activity was recently demonstrated, suggesting a role in 
hepatocarcinogenesis [62]. No known resistance mutation to antiretroviral drugs was detected in 
our dataset, which might be explained by the lack of selection pressure due to the limited use of 
the drugs in this region. 
In summary, we revealed a high prevalence of HBsAg carriers among adults and the occurrence 
of HDV co-infection in the general population of the Offin river valley of Ghana. A low genetic 
diversity was found among the HBV sequences, and HBV/E was the only genotype detected. We 
conclude that in addition to strict adherence to the EPI schedule for children, there is need for an 
anti-hepatitis B campaign in the form of screening and assessing the severity of liver disease in 
order to select individuals eligible for treatment, prioritizing patients with advanced stage liver 
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disease. While in resource-rich countries effective treatments for chronic hepatitis are widely 
available, access to antiviral therapy is restricted in developing countries and should be urgently 
improved. Challenges associated with this endeavor have to be faced from the perspectives of 
global health and social justice [63]. 
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6.7 Figures 
 
Figure 6.1. Study area. Map of Ghana with the Offin river valley and surrounding countries. 
The 13 study communities along the Offin River are indicated as multicolored dots: Bedomase 
(BDS); Krakrom (KKS); Kapro (KPS); Akomfore (AFS); Ntobroso (NBUS); Achiase (ABUS); 
Keniago (KGS); Tontonkrom (TNS); Dominase (BUDS); Wromanso (WMS); Nkotumso (NKS); 
Mfantseman (MFS); Pokukrom (PKS). The grey lines in the Ghana map indicate the borders of 
the Ghanaian regions. The background maps were created using the ArcMap program in ArcGIS 
v.10.0 and were modified with Adobe Photoshop CS6. 
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Figure 6.2. Age distribution and percentage of HBsAg carriers. A stacked graph of the total 
number of study participants for each age group (white bar) and of the corresponding number of 
HBsAg carriers (black bar) (left y-axis) is shown. The percentage of HBsAg carriers for each age 
group (right y-axis) is indicated by squares. 
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Figure 6.3. Phylogenetic reconstruction of world-wide  and Offin river valley HBV 
sequences based on the pre-S/S region. A maximum-likelihood phylogenetic tree of HBV pre-
S/S sequences obtained in this study (red dots) together with publically available sequences 
covering all HBV genotypes (multicolored dots) was constructed with 1000 bootstrap replicates 
using the Kimura 2-parameter +G +I model [41] contained in MEGA6 [42]. The tree is drawn to 
scale, with branch lengths corresponding to the number of substitutions per site.  
Reference sequences retrieved from GenBank are for genotypes A (AY233278, HE576988, AM184126, 
AM180623, FJ692609, GQ331047, FN545833), B (AB073842, AB073836, AB033555, AB100695, AB219427, 
DQ463789, EF473977, AP011093, GQ358145), C (AF223954, AB033556, X75656, AB048704, AB241109, 
AP011102, AP011104), D (JF754615, EU594428, AY233291, KF192838, GQ205378, AB493846, FJ904430, 
FN594771, JN664919), E (circles without fill: AB205192, AB106564, DQ060830, AB201290, AB205188, 
AB091255, AB091256, HM363611, FN594765, AB205191, AB205190), F (AF223964, X69798, AB036914, 
DQ823087), G (AB056513, EF634480), H (EU498228, EF157291), I (FJ023660), and J (AB486012). The sequence 
of a Woolly monkey HBV was included as an out-group. 
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Figure 6.4. Phylogenetic reconstruction of HBV/E sequences. A maximum-likelihood 
phylogenetic tree based on the pre-S/S gene region sequence (1,200 bp) was constructed using 
the Kimura 2-parameter +G model [41] embedded in MEGA6 [42]. While HBV sequences 
obtained in this study are indicated as multicolored dots (according to village of residence), HBV 
genotype E sequences retrieved from GenBank are depicted as empty circles (accession numbers 
(origin): AB205192 (Ghana), AB106564 (Ghana), DQ060830 (Madagascar), AB201290 
(Benin), AB205188 (Ghana), AB091255 (Côte d'Ivoire) AB091256 (Côte d'Ivoire), HM363611 
(Nigeria), FN594765 (Niger), AB205191 (Ghana), AB205190 (Ghana)). The sequence of the 
genotype D AY233291 from South Africa was included as an out-group. 
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6.7.1 Supporting Figures 
 
 
Figure S6.1. Distribution of study participants by age group and residential community. 
. 
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6.8 Tables 
 
Variables 
Community* Total 
ABUS AFS BDS BUDS KPS KGS KKS MFS NKS NBUS PKS TNS WMS --- 
Health districts‡ AM AM SS UDW AN AW SS UDE UDW AM UDE AW AC --- 
Community Infrastructure  
Road network§ C2 C3 C2 C1 C1 C2 C3 C3 C1 C2 C3 C2 C3 --- 
Social infrastructure# SRM SR SRM SRMH SR SRMH - SRM SRMH SRMH SRMH SRMH SR --- 
Surveyed Population  
Total inhabitants, n 1,900 1,016 1,688 2,802 692 3,350 111 303 2,518 1,949 900 2,945 216 20,390 
Recent travel history, n 
(%) 
518 
(27.3) 
350 
(34.4) 
546 
(32.3) 
1,360 
(48.5) 
192 
(27.7) 
1,156 
(34.5) 
67 
(60.4) 
78 
(25.7) 
1,120 
(44.5) 
758 
(38.9) 
409 
(45.4) 
1,117 
(37.9) 
141 
(65.3) 
7,812 
(38.3) 
Recent contact with 
major cities, n (%) 
354 
(18.6) 
150 
(14.8) 
357 
(21.1) 
1,036 
(37.0) 
96 
(13.9) 
705 
(21.0) 
11 
(9.9) 
10 
(3.3) 
462 
(18.3) 
446 
(22.9) 
281 
(31.2) 
662 
(22.5) 
89 
(41.2) 
4,659 
(22.8) 
Study Participants  
Total, n 117 113 112 91 111 107 71 114 80 123 116 94 74 1,323 
Females, n (%) 64 
(54.7) 
64 
(56.6) 
68 
(60.7) 
48 
(52.7) 
62 
(55.9) 
66 
(61.7) 
40 
(56.3) 
65 
(57.0) 
48 
(60.0) 
77 
(62.6) 
82 
(70.7) 
49 
(52.1) 
48 
(64.9) 
781 
(59.0) 
HBsAg sero-
prevalence, n (%) 
3 (2.6) 12 
(10.6) 
3 
(2.7) 
9 (9.9) 11 
(9.9) 
2 (1.9) 7 
(9.9) 
6 
(5.3) 
10 
(12.5) 
11 
(8.9) 
10 
(8.6) 
14 
(14.9) 
9 
(12.2) 
107 
(8.1) 
Anti-HDV antibody 
sero-prevalence among 
HBsAg pos, n (%) 
1 
(33.3) 
0 (0) 0 (0) 1 
(11.1) 
0 (0) 0 (0) 0 (0) 0 (0) 3 (30) 0 (0) 0 (0) 3 (21) 1 
(11.1) 
9 (8.4) 
Table 6.1. Characteristics of the study population and HBsAg and anti-HDV antibody seroprevalence. * ABUS = Achiase; AFS 
= Akomfore; BDS = Bedomase; BUDS = Dominase; KPS = Kapro; KGS = Keniago; KKS = Krakrom; MFS = Mfantseman; NKS = 
Nkotumso; NBUS = Ntobroso; PKS = Pokukrom; TNS = Tontonkrom; WMS = Wromanso 
‡ AM = Atwima Mponua district; SS = Sekyere south district; UDW = Upper Denkyira West district; AN = Atwima Nwabiagya 
district; AW = Amansie West district; UDE = Upper Denkyira East district; AC = Amansie Central district 
§ C1 = asphalt road surface, major road connecting one district capital to another with relatively high traffic volume; C2 = gravel road 
surface, major road connecting one town to another with relatively low traffic volume; C3 = gravel road surface, minor road 
connecting one town to another with cars sparingly plying the road 
# S = school; R = religious facilities; M = central market; H = health center 
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Pre-S region S region 
 
Met
83
 
 
Gly
71
-Asn
97
, 
Arg
112
-Arg
136
 
 
Val
135
-Phe
140
 
 
Met
119
 
 
Thr
57
 
 
Gln
101
 
 
Ile
110
 
 
Ser
114
 
 
Leu
127
 
 
Ser
140
 
 
Ser
143
 
 
Gly
159
 
 
Trp
182
 
 
Leu
216
 
AFS097 . . . . . . . . Pro . . . . . 
AFS115 . . . . . . . . Pro . . . . . 
BUDS005 . . . . . His . . . . . . * . 
BUDS006 . . . . . . Leu Ala . . . . . . 
BUDS073 . . . . . . . . . . . . . * 
KKS062 . . . . . . . Pro . . . . . . 
KKS064 . . . . . . . . Ile . . . . . 
KPS088 . . . . . . . . . . . Ala . . 
MFS048 . . . . . . . . . . Leu . . . 
NBUS058 . . . Thr . . . . . . . . . . 
NBUS062 . . . . . . . . . . . . . . 
NBUS067 Lys . . . . . . . . . . . . . 
NBUS070 . . . . . . . Thr Pro . . . . . 
NBUS078 . . . . . His . . . . . . . . 
NKS010 . . . Ile . . . . . . . . . . 
PKS034 . ------ . . . . . . . . . Ala . * 
PKS077 . . ------ . . . . . . . . . . . 
TNS014 . . . . Ile . . . . Leu . . . * 
TNS055 . . . . . . . . . . . . . * 
TNS065 . . . . . . . . . . . . . * 
TNS091 . . . . . . . . . . Leu . . . 
WMS009 . . . Thr . . . . . . . . . * 
Table 6.2. Comparison of deduced amino acids of sequences obtained in this study and HBV/E consensus. Only relevant 
mutations and deletions described in the text are shown. *nonsense mutations 
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6.8.1 Supporting Tables 
 Community# 
Total 
ABUS AFS BDS BUDS KPS KGS KKS MFS NKS NBUS PKS TNS WMS 
Offin cluster sequences (n) 0 4 0 5 4 1 2 2 2 2 4 4 3 33 
Pan-African cluster 
sequences (n) 
0 2 1 4 2 0 3 2 0 3 1 1 0 19 
Total 0 6 1 9 6 1 5 4 2 5 5 5 3 52 
Table S6.1. Origin of HBV sequences belonging to the Offin and pan-African clusters. #Achiase (ABUS); Akomfore (AFS); 
Bedomase (BDS); Dominase (BUDS); Kapro (KPS); Keniago (KGS); Kakrom (KKS); Mfantseman (MFS); Nkotumso (NKS); 
Ntobroso (NBUS); Pokukrom (PKS); Tontonkrom (TNS); Wromanso (WMS) 
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Community/ 
ID 
Gender Age Additional HBsAg 
carriers in household 
Relevant 
mutations  
(S region) 
Anti-HDV 
antibody 
positivity 
AFS068 Female 12 NI
#
  No 
AFS080 Male 18 1  No 
AFS097 Female 33 NI sL127P No 
AFS101 Female 38 NI  No 
AFS113 Female 4 NI  No 
AFS115 Male 27 NI sL127P No 
BDS103 Male 27 1  No 
BUDS005 Female 55 NI  No 
BUDS006 Female 21 NI  No 
BUDS015 Female 13 NI  No 
BUDS023 Male 13 NI  No 
BUDS033 Female 23 NI  No 
BUDS038 Male 8 NI  No 
BUDS051 Female 17 NI  No 
BUDS073 Female 35 1 (BUDS081) sL216* Yes 
BUDS081 Male 21 1 (BUDS073)  No 
KGS053 Female 32 NI  No 
KKS011 Male 17 NI  No 
KKS013 Male 18 2 (KKS062, KKS064)  No 
KKS033 Male 15 NI  No 
KKS062 Female 10 2 (KKS013, KKS064)  No 
KKS064 Male 15 2 (KKS013, KKS062) sL127I No 
KPS021 Male 4 NI  No 
KPS029 Male 24 NI  No 
KPS078 Male 8 1  No 
KPS088 Female 19 NI  No 
KPS091 Male 36 1 (KPS094)  No 
KPS094 Male 13 1 (KPS091)  No 
MFS014 Female 31 NI  No 
MFS022 Female 5 NI  No 
MFS043 Male 19 NI  No 
MFS048 Female 25 NI sS143L No 
NBUS058 Female 42 NI  No 
NBUS062 Female 42 1 (NBUS070)  No 
NBUS067 Male 45 NI  No 
NBUS070 Female 23 1 (NBUS062) sL127P --- 
NBUS078 Male 29 NI  --- 
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NKS010 Female 42 1 (NKS020)  --- 
NKS076 Male 34 NI  Yes 
PKS003 Male 27 NI  No 
PKS034 Male 9 2 sL216* No 
PKS066 Female 13 NI  No 
PKS077 Female 35 NI  No 
PKS096 Female 17 NI  No 
TNS014 Female 50 1 sS140L, sL216* No 
TNS055 Male 28 NI sL216* No 
TNS065 Female 55 NI sL216* No 
TNS088 Male 14 2 (TNS091)  Yes 
TNS091 Male 16 2 (TNS088) sS143L No 
WMS009 Female 23 2 (WMS008) sL216* No 
WMS081 Male 25 NI  No 
WMS082 Male 12 NI  No 
Table S6.2. Demographic and serological data of HBsAg carriers, for which sequence 
information is available. # NI = not identified 
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7.1 General remarks  
Following the first definitive clinical description of M. ulcerans infections in 1948 and the 
declaration of the disease as a considerable Public Health burden at the WHO meeting in 
Yamoussoukro in 1998, research on BU has gained increased attention. The intensified research 
and control efforts invested into BU since then have primarily reflected on the improvement of 
treatment and diagnosis and have also led to a considerable demystification of the disease in the 
affected populations. Nevertheless, several aspects of BU epidemiology and transmission have 
still not been fully elucidated. Through collaborative studies embedded in the Stop Buruli 
Initiative, the NMIMR and the Swiss TPH have shed light on the epidemiology and transmission 
of BU in the Densu river valley of Ghana [1–3]. The collaborative research was then extended to 
the Offin river basin which has been known to be the most endemic area in Ghana for many 
years. By this extension, we anticipated that findings from this PhD study will add on to what we 
currently know from the studies along the Densu river and in the bigger picture, contribute to the 
knowledge of BU epidemiology and M. ulcerans transmission in Ghana and globally. 
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7.2 Control of BU and other neglected tropical diseases in the Offin river 
basin 
 
7.2.1 Impact of early case detection and treatment of BU on disease control 
An important aspect of infectious disease control is the identification of risk factors that increase 
the probability that the host will come into contact with the pathogen. Understanding of risk 
factors makes it possible to identify preventable risks and to implement effective public health 
measures. This has not been possible with BU, as the definite mode of transmission is not 
known. Moreover, there is no effective vaccine. BU control has therefore relied solely on early 
case detection and treatment with a combination of anti-mycobacterial agents. Reports from the 
most recent WHO meeting on BU indicated a reduction by more than 50% in the number of 
globally reported cases in 2014 when compared to 2009 [4]. For example in Ghana, there has 
been a steady decline in the number of new cases reported from 1,048 in 2010 to 443 in 2014 [5]. 
Since 2009, Prof. Yeboah-Manu‟s group at NMIMR under the Stop BU Initiative has 
consistently conducted together with the national BU control program active case search 
followed by laboratory confirmation of cases in endemic communities along the Densu river. 
While in the first three years the number of detected cases increased, the trend reversed within 
the subsequent three years. In recent years, there has been an increase in suspected lesions within 
the communities pointing towards an enhanced awareness among populations and health 
workers. However, the percentage of suspected cases confirmed by PCR declined steeply and 
other conditions were rather diagnosed using a differential diagnosis system (Yeboah-Manu et al. 
2015, manuscript in preparation). This downward trend seems to occur also in the BU endemic 
Offin river basin, since we detected only three PCR-confirmed cases after an exhaustive active 
case search of 20,390 inhabitants (chapter 2 of this thesis). Moreover, after employing a number 
of active surveillance strategies which included monthly household visits, we could only detect 
eight more cases post the exhaustive survey. The recent decline in reported BU cases could be 
due to the intense active case search activities conducted in preceding years. Following the 
establishment of the first BU surveillance system in Ghana in 1993, the then high disease burden 
attracted a lot of research and control activities particularly within the Amansie West District, 
which in 1999 was identified as the most endemic district in Ghana [6]. In addition to the 
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observed decline of the number of BU cases, we did not find the large late stage ulcers that the 
district was noted for, but rather, early stage lesions (Figure 7.1). We assume that these trends 
reflect the intensified continuous control activities, supported by organizations such as WHO, 
ANESVAD and Safe water under the umbrella of the BU control program of Ghana health 
service. 
 
Figure 7.1. Identification of cases with early staged lesions. All cases detected during our 
study of the BU epidemiology in the Offin river basin presented with early staged lesions. 1A 
Typical Cat I ulcer on the shoulder of one case detected in the active case search. 1B Typical Cat 
I nodule presented by a case detected by a volunteer in Achiase during a household visit. 
 
The decline in BU case numbers after case detection and successful treatment support the view 
[7] that patients with chronic active lesions may play a role in the transmission of M. ulcerans by 
shedding the bacteria from active lesions into the environment, which then becomes a source of 
infection for others. There are similarity with M. leprae infection (leprosy), where humans have 
been established as reservoirs of the pathogen and some studies have suggested that transmission 
from an environmental source to man is also likely [8–12]. However, in contrast to M. leprae, 
infections, direct person-to-person transmission of M. ulcerans seems to be rare. The widespread 
introduction of multi drug therapy for leprosy (which included rifampicin) in 1981 resulted in an 
85% reduction in globally reported leprosy cases from 4 -5 million cases in the mid 1980‟s to 
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800,000 by the year 2000 [13,14]. These parallel scenarios demonstrate that early case detection 
and treatment can facilitate an interruption of the infection cycle, thereby resulting in a decline of 
cases which eventually reflects at the national and global scale. While this positive development 
for BU is encouraging, the global research agenda that includes understanding the mode of 
transmission and the ecology of M. ulcerans should be pursued. Furthermore, these successful 
activities should be continuous, as an interruption of the disease control efforts may lead to an 
upsurge of cases as is being seen with leprosy, where countries including Bangladesh and 
Madagascar were declared by the WHO as leprosy-free some decade ago, but the disease has 
bounced back to remote and poor areas as well as the capital cities [15,16]. 
 
7.2.2 Opportunities for an Integrated Disease Surveillance and Control Response  
For many low-resourced countries, there is extensive geographic overlap and co-endemicity of 
neglected tropical diseases [17,18], which has prompted global calls for an integration of control 
strategies [19,20]. However, for many years, the link between disease surveillance and response 
in most countries within the sub-Saharan Africa region was only weak; a sign of inadequate 
preparedness to handle disease outbreaks should they occur. This led to a proposal by the 
WHO‟s Regional Office for Africa (WHO AFRO) for an Integrated Disease Surveillance and 
Response (IDSR) strategy in 1998 [21,22]. In its entirety, the IDSR strategy was meant to 
marshal the limited human and financial resources available for the different disease control 
programs (which includes the National Buruli Ulcer Control Programme) to operate a system 
that monitors disease outbreaks (at both community and district levels), conduct laboratory 
diagnoses and report outbreaks in a timely fashion. Since the implementation of the IDSR, some 
global successes have been recorded for countries like Uganda where in 2000, an outbreak of 
Ebola Haemorraghic Fever was managed within the framework of the IDSR which eventually 
led to the identification of important means of transmission of the virus [23]. In Ghana, the IDSR 
has played similar roles in cholera outbreaks and has contributed to the decline in the incidence 
of polio, measles and yellow fever which have been recorded over the years by means of its 
vertical system of operation. 
Within the framework of our BU case detection activities in the Offin river basin (Chapter 2) we 
equipped community volunteers with mobile phones to conduct monthly surveillance of BU at a 
household level. We observed that during such home visits, the volunteers seized the opportunity 
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to execute other responsibilities such as distribution of insecticide treated nets (for malaria 
control) and follow up on children who missed out on health outreach programs such as mass 
drug administration (MDA). This served as a primary indication that integration of disease 
control was feasible at least at the level of early case detection and treatment which forms the 
core of strategies mapped out for most neglected tropical diseases. In addition, with one round of 
exhaustive active BU case search, we could gather case data for other diseases such as 
tuberculosis and leprosy, demonstrating an opportunity to cut cost by using the same number of 
staff and logistics primarily intended for investigation into the burden of BU. Furthermore, by 
collaborating with the local health staff, we screened and treated participants being followed up 
on for other endemic diseases like malaria and syphilis.  
A core component of the IDSR strategy included gathering disease data which better informs 
health policy and helps in decision making. To this end, the District Health Information 
Management System (DHIMS) in 2012 was restructured to an internet-based system of reporting 
(DHIMS II) with the overall objective of improving data quality and reliability across the various 
strata of the health system [25]. During our investigations in 2013, we observed that some 
records were still maintained on paper based platforms with a widespread loss of information 
pertaining to annual cases of BU reported for most districts. Our current mobile phone based 
surveillance system presents an opportunity to preserve the case notification records since these 
data are backed-up automatically and can be accessed at any time. By including the surveillance 
of other diseases on this platform, disease control officers can effectively monitor outbreaks of 
diseases and better co-ordinate intervention activities from the district office. For diseases like 
polio, Guinea worm infection and leprosy, where national incidence rates are close to the 
threshold set for elimination by the WHO, their individual control programs face an imminent 
threat of collapse. In view of this, the most effective way to sustain surveillance of all diseases 
with very low incidence (which currently includes BU) would be to integrate all the surveillance 
activities.  
When taken together, our surveillance system that was well developed for BU has helped to and 
may act as driving force for strengthening other surveillance activities by offering possible 
synergies and common resources to improve various aspects of public health within the river 
basin. 
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7.3 Ecology and Transmission of M. ulcerans 
7.3.1 Potential reservoirs of M. ulcerans 
The success of micro-epidemiological studies in tracking transmission routes, identifying 
infection sources as well as reservoirs of several bacterial pathogens has chiefly depended on the 
genetic delineation of isolates. The extreme lack of genetic diversity of M. ulcerans reflected by 
the inadequate resolution offered by conventional genotyping tools posed a major setback to 
micro-epidemiological studies on BU for several years [26–30]. Molecular tools employed have 
however evolved over the years with each new approach shedding more light on the 
epidemiology of the pathogen by strain delineation. For example, variable number of tandem 
repeat (VNTR) typing offered a limited resolution by differentiating a collection of strains from 
Ghana into three VNTR types [31]. Beyond the district level, the VNTR typing however failed to 
discriminate the strains; a setback which was overcome with the advent of whole genome 
sequencing. Based on the identification of informative single nucleotide polymorphisms (SNPs) 
through whole genome analysis of a collection of isolates from BU patients in Ghana, which 
included representatives of the three previously identified VNTR types [31,32], a real-time PCR 
SNP typing method was developed [3]. Subsequent SNP typing of a collection of strains from 
residents of the Densu river basin resulted in the discrimination of these strains into 10 different 
SNP haplotypes [3]. Linking of the strains to the residential villages of the patients revealed 
geographical clustering of several SNP haplotypes with one haplotype (founder haplotype) being 
widely distributed. This led to the hypothesis that the “founder haplotype” was first introduced to 
the endemic area and with time accumulated some mutations causing it to evolve into the other 
(clustered) haplotypes. In addition, this spoke for a reservoir with very limited mobility.  
A more recent study [33] was based on the whole genome analysis of a collection of 18 isolates 
from the Agogo community in the Ashanti region of Ghana. Based on their SNP profiles, 10 of 
the 18 isolates clustered with other strains from the neighboring Amansie West district. This 
implied that within the broader context of the Ashanti region, the “Amansie West genotype” 
(Agogo-1) is a local clonal complex which had spread and persisted within the region. Within the 
same collection of strains, a second clonal complex, “Agogo-2” was also identified. This 
complex, which clustered with a Nigerian isolate, was however randomly distributed within the 
endemic region implying co-existence of both clonal complexes. Consistent with these findings, 
we observed by whole genome and phylogeographic analysis of a limited number of strains, the 
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presence of two distinct clonal complexes within the Offin river valley (Chapter 5). Both were 
represented by strains isolated from patients in 2004 and 2013 and neither clustered 
geographically. While in the Densu river basin [3] and in two BU endemic areas of Cameroon 
[34] single local clonal complexes were found – indicative for M. ulcerans reservoirs with 
limited mobility - our current findings along with the recent study from the Agogo community 
[33] suggest that members of local clonal complexes of M. ulcerans may be carried occasionally 
over wide distances to other areas and establish there. However, the nature of this mobile 
reservoir in African endemic settings is yet to be explored. 
In this context, environmental studies inspired by outbreaks of BU in Australia led to the 
detection of M. ulcerans DNA in mosquitoes and feces of possums. A number of possums also 
had BU-like lesions containing M. ulcerans bacteria, which led to a hypothesized mode of 
transmission with the possums acting as probable reservoirs and mosquitos as potential vectors 
[35]. The search for similar mammalian reservoirs in African BU endemic settings has however 
yielded futile results. A field capture of over 700 rodents in high and low endemic regions of 
Uganda in 1972 led to identification of some rodents with mycobacterial infections, none of 
which was caused by M. ulcerans [36]. A similar study also involving the capture of 348 small 
mammals in six villages in Benin found no M. ulcerans DNA in pooled samples of the captured 
animal body parts or feces [37]. Within the context of this PhD we conducted an extensive 
environmental sampling in communities along the Offin River (Aboagye et al., 2015 manuscript 
in preparation) and did not encounter any domestic or wild mammals with BU-like lesions. 
Furthermore, the natives of the communities we worked in denied knowledge of the existence of 
such animals. The analysis, which was supported by a colleague PhD student, however found M. 
ulcerans DNA positivity among soil and vegetation samples. This observation together with the 
downward trend of new cases speaks more for humans as likely reservoirs of M. ulcerans in the 
African endemic settings. 
Movements of patients with active lesions into new geographical regions on a county-, region- or 
community-scale in West Africa, may lead to an introduction of new variants. Subsequently, by 
means of activities that facilitate the dissemination of the bacteria into the environment, other 
inhabitants that come into contact with the contaminated source may get infected.  
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7.3.2 Evidence for the presence of M. ulcerans in the environment.  
Efforts at elucidating the ecology of M. ulcerans in the environment was inspired by several 
epidemiological studies that have consistently associated activities or residency near water 
bodies with BU [38]. Ideally, successful isolation and characterization of the pathogen from the 
environment could have served as definite proof of which specific part of the environment is 
responsible for transmission of M. ulcerans to man. However, M. ulcerans has a extremely slow 
growth rate, making it very likely to be outgrown by other faster growing environmental 
organisms (including decontamination-resistant other environmental mycobacterial species) on 
artificial media. In view of this, several attempts at cultivating the bacteria from environmental 
source has been unsuccessful with the description of only one environmental isolate published so 
far [39]. While detection of the M. ulcerans DNA sequences IS404, IS2606 and KR by PCR 
[40,41] is not a definitive proof of viability, it has been utilized to demonstrate the presence and 
spread of the bacteria in several environmental studies. Based on the high positivity rate of 
detection of M. ulcerans DNA in a village along the Densu river valley, a recent isolate from the 
environment has been obtained and is currently being further characterized (personal 
communication, Prof. Dorothy Yeboah-Manu). 
Within the framework of this PhD study, we conducted an extensive environmental sampling and 
analysis of 1166 samples from communities along the Offin. We demonstrated that in 
accordance with the low prevalence of BU cases detected within the river basin (Chapter 2), the 
proportion of environmental samples positive for M. ulcerans was extremely low (3.9%) when 
compared with the 22.5% recorded for the Densu river valley (Aboagye et al., 2015 manuscript 
in preparation). In addition to recording a higher number of BU cases when compared to the 
Offin river, communities along the Densu had higher sero-positivity rates of 33% for the M. 
ulcerans 18KDa small heat shock protein (shsp) [2], when compared to 18% for those along the 
Offin (Chapter 4).  
Altogether, we conclude that M. ulcerans is contracted through environmental exposure. 
Furthermore, we hypothesize that there is a correlation between sero-positivity, incidence of BU 
cases and the rate of detection of M. ulcerans DNA in the environment, if all three parameters 
are monitored within a study site. 
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7.3.3 Exploring the relationship between exposure to and transmission of M. ulcerans 
The M. ulcerans 18KDa shsp has been identified and characterized as a suitable antigen for 
assessing the exposure of populations to the pathogen [42]. In a previous sero-epidemiological 
study conducted within the Densu river valley, individuals with antibodies against the M. 
ulcerans 18KDa shsp were identified in nearly all age groups under study [2]. However, none of 
the participants within that study was below 5 years of age, making it impossible to determine 
the age of onset of sero-conversion. Within the framework of this PhD study (Chapter 3), we 
analyzed a collection of sera which included more than 100 children below 5 years of age from 
the BU endemic Densu river valley (Ghana) and Bankim health district (Cameroon). We 
observed that children below 5 years of age were less exposed to the pathogen when compared to 
older children. None of the study participants <4 years old contained antibodies against the 
pathogen in their sera. In accordance with this observation, we found that by estimating the age 
at which patients within the Offin basin contracted BU, children below the age of 5 years were 
under-represented although the majority of our cases fell below 15 years of age (chapter 2 of this 
thesis). We therefore conclude that exposure to M. ulcerans starts at around 5 years of age which 
coincides with the age when children use to acquire new activities and expand their range of 
movement. Typically within our study communities along the Offin, these activities may include 
schooling, expansion of social networks (particularly making and visiting new friends) and 
execution of duties, such as the collection of water and fire wood, which eventually increases the 
likelihood of them coming into contact with the environment contaminated with M. ulcerans at 
the periphery of the community. 
Within the last decades researchers have postulated different modes of M. ulcerans transmission. 
Theories that have been proposed to explain the mechanism of M. ulcerans infection include 1) 
inhalation of aerosolized M. ulcerans from contaminated water [43,44], 2) acquisition of M. 
ulcerans through bite of an insect or other vector, and 3) contamination of existing wounds or 
sites of trauma by environmental reservoirs such as soil, vegetation and water among others [45]. 
However none of these theories have been confirmed.  
To further shed light on the possible transmission routes of M. ulcerans, we collected blood 
serum samples from a total of 1,352 individuals living along the Offin river and compared the 
first humoral immune response to M. ulcerans with pathogens with different modes of 
transmission. Contrary to what we observed for exposure to M. ulcerans, nearly all children 
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below 4 years had antibodies against the mosquito-transmitted Plasmodium falciparum AMA-1 
antigen in their sera, which casted doubt on the involvement of mosquitos in the transmission of 
M. ulcerans. Some case control studies have identified using bed nets [46] and repellants [47] as 
protective factors against M. ulcerans infection. Based on our finding, we infer that potential 
insect vectors localized within the homes are not likely to play a role in the transmission of the 
pathogen. Since we observed an early serological response to antigens of soil-transmitted 
Strongyloides, an involvement of the soil around the houses in the transmission of M. ulcerans is 
not likely. In contrast, we found that the serological response to both egg and adult worm 
antigens of the water-related Schistosoma parasite sets in as late as the response to M. ulcerans, 
strongly inferring that transmission of M. ulcerans is most likely connected to an environmental 
reservoir in the aquatic ecosystem outside of the limited movement range of small children. Still 
unclear is the mechanism of entry of the bacteria into the skin; inhalation of aerosolized M. 
ulcerans from contaminated water is now considered to be very unlikely. When placed within 
the context of the remaining two hypotheses explaining the entry of M. ulcerans into humans 
[46,48], our findings indicate that infection may occur through both contact between an existing 
wound and an environmental source (potentially mud [49]) contaminated with M. ulcerans  and 
inoculation of the pathogen into the skin via an unknown vector associated with stagnant water 
bodies. 
Overall, we conclude that exposure to M. ulcerans starts at around five years of age, coinciding 
with the age at which children take on new activities and increase their movement range to 
include going out of their households and having more intense contact with the periphery of the 
community. In addition, by comparing the age pattern of the first humoral immune response to 
M. ulcerans with that of pathogens with different modes of transmission, we are of the opinion 
that the exposure is most likely by contact with M. ulcerans present in the aquatic ecosystem at 
the periphery of the communities. 
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7.4 Hepatitis B virus infection: burden, genetic diversity and implications for 
BU treatment 
Management of patients with co-infection of two or more diseases represents generally a 
complex challenge for clinicians and public health staff. With the exception of HIV co-
infections, which have gained a lot of research attention due to the aggressive acceleration of 
clinical BU symptoms [50–57], studies on the co-infection of BU with other diseases are scanty. 
To the best of our knowledge, no study has been conducted on the co-infection of BU with HBV, 
which should be of public health concern. Rifampicin is the only highly effective anti-
mycobacterial drug against BU and it should be of major concern, that, overt liver damage has 
been associated with TB cases with pre-existing HBV infection (both carriers and diseased) 
undergoing rifampicin chemotherapy [58–61].  
While the highest burden of HBV infection occurs in sub-Saharan Africa and Asia, most of the 
populations are unware of their HBV infection status [62].Within the framework of this PhD 
thesis, we analyzed the prevalence of the hepatitis B surface antigen (HBsAg) in sera of 
individuals living in BU endemic communities of the Offin river valley as an indication of 
chronic HBV carriage. We observed that the HBsAg carrier rate among children below 12 years 
of age was low with 1.8% when compared to older participants >12 years, where the carrier rate 
was as high as 11.1% (Chapter 6). There has been an effective vaccine against HBV since the 
late 1970‟s [63], however, it was not until 2002 that vaccination against the virus was 
incorporated into Ghana‟s immunization schedules following the WHO Expanded Program on 
Immunization (EPI). Specifically for all seven health districts of the Offin river in which we 
worked, the vaccination of infants against HBV started around 2002 (personal communication 
with all disease control officers). While the low infection rate recorded for children <12 years 
reflects the 11 year period of running the EPI with inclusion of the HBV vaccine, periodic 
studies are needed to assess the effectiveness of the program.  
While all HBV isolates from the Offin river basin were characterized as genotype E, 
phylogenetic analysis based on the sequence analysis of the pre-S/S region revealed clustering of 
a number of the Offin strains with those of other neighboring West African countries, 
particularly Niger, Nigeria, Benin and Cote D‟Ivoire. The Offin river which has been a place of 
small scale gold mining for many centuries, has produced more gold than any other river system 
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in Ghana [64]. Over the years, there has been upscaling of small scale mining activities coupled 
with the influx of artisans from other regions in Ghana as well as citizens of other countries. 
During our exhaustive survey of the Offin river population (Chapter 2), we observed a number of 
West African nationals (particularly from Niger, Nigeria and Benin) resident within the river 
basin for several years. While none of the samples we analyzed was drawn from other nationals, 
the possibility that a foreign variant was introduced into the river basin cannot be ignored. 
Recently, a new BU infection focus has been identified within the Dunkwa Offin municipality 
(personal communication, Mr George Amofa of the District health directorate, Upper Denykira 
East). Given the high HBV positivity rates (>10%) recorded here for some communities, we 
recommend that new BU cases should be screened for HBV infection before commencing 
rifampicin treatment in all areas where co-infection of BU and HBV is likely. Given the evidence 
of potential hepatotoxicity associated with the use of rifampicin, there is a challenge of managing 
BU patients pre-infected with HBV. To address this we recommend the re-consideration of 
thermotherapy [65–67] as an alternative treatment for BU. As mentioned in Chapter 2, early case 
detection would potentially guarantee that cases detected will present with early stage lesions 
which can be managed relatively easily by thermotherapy [68]. In this context it should also be 
mentioned that major research efforts have been invested into the search for a replacement of 
streptomycin by another antibiotic, because of the severe side effects and numerous challenges 
associated with streptomycin administration. 
Altogether, we conclude that transmission of HBV along the Offin river is mainly horizontal. 
Additionally, there are preliminary indications that the expanded EPI program which includes 
vaccination of infants against HBV infection is effective. We recommend based on our findings 
that screening and vaccination of the adult population should be considered. 
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7.5 Outlook 
Based on the multidisciplinary approach to investigate the various arms of this PhD study, we 
have identified key findings which add to the existing knowledge of the epidemiology and 
transmission of M. ulcerans in Ghana and globally. As an outlook, we highlight findings, 
achievements, conclusions and areas of future research priorities below: 
i) We have established a field study site along the Offin river and demonstrated the 
decline in BU cases over the years. The study site subsequently served as a well 
characterized epidemiological setting for the investigation of other aspects of this 
thesis as well as for follow up of study participants. 
ii) We have established an active BU surveillance system which can be integrated with 
surveillance of other neglected tropical diseases to save cost and maximize resources 
directed and allocated for control of neglected tropical diseases within the Offin 
basin. Furthermore the electronic platform for data collection on the incidence of BU 
can be incorporated to address the gaps in data storage at the district level. 
iii) We have identified the spatiotemporal co-existence of two M. ulcerans clonal 
complexes by whole genome sequencing analysis of a limited number of clinical 
isolates from the Offin river. This implies that M. ulcerans strains are occasionally 
carried from a BU endemic site to a distant site and can subsequently establish as 
pathogen at the new site. Whole genome sequencing of larger strain collections of 
different geographic origin will help shedding more light on this finding. 
iv) We have demonstrated that exposure of populations to M. ulcerans generally starts at 
around 5 years of age. This may be associated with movement of children away from 
their homes and having contact with the periphery of the community, including water 
bodies or other sources potentially contaminated with M. ulcerans. Longitudinal 
follow up of children coupled with environmental surveillance and behavioral studies 
may shed more light on reservoirs and transmission routes of M. ulcerans.  
v) We found strong evidence that vaccination against HBV with the current DTPHH 
vaccine is effective. While strict adherence to the vaccination protocol is encouraged 
for newly-born infants, there is a need for a health campaign to test and vaccinate or 
treat the adult population. Detailed studies are required to assess the efficiency of the 
vaccination program periodically.  
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